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CHAPTER I: DISEASE HISTORY 
 
 
1.1 FIRST HIV/AIDS REPORTS 
 
The HIV/AIDS pandemic started 25 years ago. In 1981 clinicians in New York reported the 
increased incidence of the previously rare diseases Kaposi Sarcoma (KS) and Pneumocystis 
carinii pneumonia (PCP) in a population of homosexual men1. Soon other risk groups were 
identified (intravenous drug users, heterosexuals with high promiscuity and individuals 
receiving blood products), which led to the suspicion of an infectious agent.  
Omnipresent organisms not normally causing health problems were inexplicably responsible 
for serious clinical deterioration and even death. It was discovered that these opportunistic 
infections (OI’s) were related to the then unexplained cellular immune failure; called 
‘Acquired Immune Deficiency Syndrome’ (AIDS). Two years later, the chronic infection, 
leading to AIDS, was proven to be caused by a retrovirus, named Human Immunodeficiency 
Virus (HIV) 2.  
The main explanation for the immune deficiency caused by HIV-infection was found to be the 
progressive loss of CD4 T cells. These cells, central in the regulation of humoral and cellular 
immune effector functions, were found to decline due to direct viral cytotoxicity and more 
importantly indirect apoptosis inducing mechanisms 3. Once the CD4 T cells fall below the 
critical level of 200 cells/µl blood, the HIV-infected individual becomes extremely 
susceptible to develop opportunistic infections 4.  
 
 
1.1 THERAPY  
 
In 1987, the first antiretroviral (ARV) drug Azidothymidine (AZT) was approved by the Food 
and Drug Administration (FDA). Two years later it became obvious that AZT alone was 
unable to control viral replication in the long term. This was due to the rapid development of 
drug resistance 5.  
With time, new ARV drugs, targeting the viral Reverse Transcriptase (RT), were developed: 
they could be divided into two classes: Nucleoside/Nucleotide Reverse Transcriptase 
Inhibitors (NRTI’s) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI’s). In 
1996, another class of drugs, inhibiting the activity of the viral protease enzyme (protease 
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inhibitors: PI’s) was introduced. During that period, new hope for long term viral suppression 
arose: combinations of at least 3 different drugs of 2 distinct classes (NRTI’s, NNRTI’s or 
PI’s) were shown to suppress viral replication in the long term. This combination therapy was 
known as ‘Highly Active Antiretroviral Therapy’ (HAART).  
Indeed the introduction of HAART led to a dramatic decline in HIV-related morbidity and 
mortality: the recovery of immune functions reversed the risk to develop opportunistic 
infections. At the same time the HIV-transmission rate diminished. These trends, however, 
were only observed in the rich, western world. In Europe, the incidence of AIDS (late stage 
HIV-infection) in HIV-infected patients, declined over 4 years (between 1994 and 1998) from 
30,7 to 2,5 per 100 patients per year.  
Nevertheless, the global HIV pandemic is seriously growing. The World Health Organization 
(WHO) has set a goal of treating 3 million people with Antiretroviral Therapy (ART) by the 
end of 2005. By June 2005 only one million people were estimated to be on ART 6. This 
represents only 17% of the 5.8 million people that currently need ART. Provision of ART to 
all those in need will require a massive and unprecedented investment in health care systems 
of developing countries. In addition, scaling up HIV prevention also is a priority. A newly 
developed efficient HIV/AIDS vaccine could potentially offer the ultimate solution. However, 
there are currently no indications that such a vaccine will be available in the near future; the 
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Global AIDS epidemic 
 
Fig. 1: The global AIDS epidemic. The number of people living with HIV and AIDS and the 






In the late seventies and early eighties, a disease,
called “Slim disease”, caused more than 100 deaths in
Kasensero, a small village in Uganda (1, 2). Repeated
infections and cachexia were followed by a fatal
outcome. Because of a bloody guerr i l la war
investigations was never done. In 1981, dermatolo-
gists in New York observed a sudden higher
occurrence of a previously extremely rare skin cancer
in a population of gay men, which they first called “gay
cancer” (3). Shortly after, physicians in New York and
San Fransisco were also alarmed by a sudden rise in
occurrence of the same skin cancer; formerly known
as the Kaposi Sarcoma (KS), and an opportunistic
lung infection Pneumocystis carinii pneumonia (PCP)
(4). In those previously healthy homosexual men an
unexplained cellular immune failure was observed:
lymphopenia with a decline in number and function of
T helper cells and an inversion of the normal ratio T
helper cells / T suppressor cells. The term Acquired
Immune Deficiency Syndrome (AIDS), was defined
later the same year. Other associated opportunistic
infections were found in these (AIDS) patients:
candidiasis, toxoplasmosis, cryptococcosis, CMV
infections, etc. A similar distribution pattern to hepatitis
B infection was observed and relationships between
different cases were soon made; homosexual contact
clearly transmitting the disease. Recipients of blood or
blood derived products presenting with AIDS were
traced back to their donors dying or already dead from
AIDS (5). The modes of transmission of the immune
deficiency were found to be sexual intercourse,
through blood products or needle sharing and from
mother to child, pointing to a transmissible infectious
agent. The isolation of the virus responsible for AIDS
was accomplished in 1983 by scientists of the Institute
Pasteur in France (6). The virus found, was first called
HTLV-III /LAV (human T-cell lymphotropic virus-type III/
lymphadenopathy-associated virus). Later an
international committee named the virus Human
Immunodeficiency Virus (HIV). In 1985 an antibody
test was developed and approved by the FDA, so that
blood products could be screened. After infection, the
virus causes AIDS after a variable time. When a
person gets infected by the virus, the immune system
will be attacked, leading to a cellular immune
deficiency, presented as a decrease in CD4 T cells.
This explains the sensibility for opportunistic infections
and different cancers, by the presence of which AIDS
is defined. The CD4 T cell decline is the consequence
of immune activation and the subsequent apoptosis of
CD4 T-cells, rather than the cytopathic effect of the
virus.
The origin of the virus 
A retrospective study searching for the origins of the
HIV virus could detect the virus in the blood of a man
who died in 1959 (7). The patient had symptoms of
sickle cell anemia and lived in Leopoldville, now
Kinshasa in the former Belgian Congo. The sequence
of the virus detected in this man lies near the
ancestral sequence of the subtypes B and D,
suggesting that the ancestral HIV-1 must have existed
only a few years before that time. Other studies based
on mathematical models of the genetic evolution of
the virus estimated the ancestral HIV infection
between 1915 and 1940 (8). In Europe the first
documented patients were a Norwegian family (9); the
man, a sailor, probably infected his wife, who in turn
transmitted the virus to their child. They all died of
Journal of Biological Regulators and Homeostatic Agents
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opportunistic infections. The infection in this man
probably dated from before 1966.
The HIV virus is thought to originate from closely
related monkey viruses; Simian Immunodeficiency
Viruses (SIV). More than 25 species of monkeys
harbour SIV (10); as natural host and are not
suffering any damage to their immune system. In
humans two big classes of HIV can be found: HIV-1,
the most prevalent and HIV-2, especially found in
West-Africa. HIV-2 is genetically closely related to
SIVsm found in the sooty mangabey (11), native to
West-Africa, while HIV-1 is related to SIVcpz found
in a subspecies of chimpanzees native to West
Equatorial Africa (12), which share 98% of their
genome with humans. Transmission must in one or
another way have taken place. The exact mode of
transmission, however, is not known but several
hypotheses exist, although most of them do not
agree with HIV phylogenetic studies. A first theory is
based on the fact that in some regions monkeys are
hunted, killed and eaten. Another hypothesis is
based on medical research programs; in some
studies blood of chimpanzees, sooty mangabeys and
macaques was injected in healthy volunteers to
study the transmission of malaria (13). A third
hypothesis is the introduction of the virus in humans
through the use of a polio vaccine, produced in
monkeys or on monkey kidney cells (14). The polio-
vaccination trials were performed in the former
Belgian Congo in the fifties. A fourth hypothesis is
the transmission of the virus through an
experimental hepatitis B vaccine that was given to
homosexual men in New York and to black people in
Central Africa (15). Some people believe that the
virus was genetical ly engineered in order to
eliminate some populations. All these hypotheses
are sources of continuing debate and speculation.
Spread of the virus
Probably the virus originally entered into the human
population in Africa. Cross-over, however, could have
taken place on several occasions (16). The spread in
Africa was favored by the developing health care
system after the second world war; syringes, used
several times, polygamy, urbanization and modern
transport were factors stimulating the spread of the
virus. The role of international travel can’t be
overlooked; the possibly imaginative story of “patient
Zero” (5), a flight attendant, illustrating this. “Patient
Zero” would have traveled extensively worldwide, while
infecting a lot of people. The story says that a lot of the
early cases could be traced either directly or indirectly
to sexual contacts of this patient. Epidemiological
characteristics of the epidemic, however, are different in
the developing world compared to industrialized
countries: the developing countries showing more
heterosexual transmission and a much faster spread of
the infection. In the United States and Europe the high
risk groups are homosexual males, intravenous drug
users and people receiving blood products, while in
recent years the contribution of heterosexual infection
is relatively rising. In the industrialized world prevalence
is still rising also because of the access to medication
and the decline in mortality. In the developing world
heterosexual and vertical transmission are the most
frequent routes of transmission. The probability of
transmission being higher from men to women than the
reverse, women are infected at a younger age. Vertical
transmission, reaching up to 30%, occurs during
TABLE I - REGIONAL HIV/AIDS STATISTICS AND FEATURES, END OF 2003
Region Adults and children Adults and children Adult Adult and child
living with HIV/AIDS newly infected with HIV prevalence (%)* deaths due to AIDS
Sub-Saharan Africa 25.0-28.2 million 3.0-3.4 million 7.5-8.5 2.2-2.4 million
North Africa 470 000-730 000 43 000- 67 000 0.2-0.4 35 000-50 000
South & South-East Asia 4.6-8.2 million 610 000-1.1 million 0.4-0.8 330 000-590 000
East Asia & Pacific 700 000-1.3 million 150 000-270 000 0.1-0.1 32 000-58 000
Latin America 1.3-1.9 million 120 000-180 000 0.5-0.7 49 000-70 000
Caribbean 350 000-590 000 45 000-80 000 1.9-3.1 30 000-50 000
Eastern Europe & Central Asia 1.2-1.8 million 180 000-280 000 0.5-0.9 23 000-37 000
Western Europe 520 000-680 000 30 000-40 000 0.3-0.3 2 600-3 400
North America 790 000-1.2 million 36 000-54 000 0.5-0.7 12 000-18 000
Australia & New Zealand 12 000-18 000 700-1 000 0.1-0.1 <100
Total 40 million 5 million 1.1% 3 million
(34-46 million) (4.2-5.8 million) (0.9-1.3%) (2.5-3.5 million)
*The proportion of adults (15 to 49 years of age) living with HIV/AIDS in 2003, using 2003 population figures
The ranges around the estimates in this table define the boundaries within which the actual numbers lie, based on the best
available information. These ranges are more precise than those of previous years, and work is under way to increase even
further the precision of the estimates that will be published in 2004
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pregnancy, delivery or breastfeeding when no
treatment is available. In the industrialized world vertical
transmission dropped to less than 1% through the
introduction of therapy.
Sub-Saharan Africa is the most affected region
where two thirds of the people with HIV/AIDS are
living (16, 17) (Tab. I, Fig. 1). Prevalence varies greatly
between the different countries. In South Africa and
Zambia the prevalence in adults is 20% while in
Gambia and Somalia less than 2% of the adults are
infected. In four southern African countries infection
rates are even above levels that were thought
impossible; Botswana (37.5%), Lesotho (31.5%),
Swaziland (38.6%) and Zimbabwe (33.7%).
Trends differ from country to country: in Uganda the
prevalence dropped over a 10 year period from 30%
to 6% at the beginning of this decade and it continues
to decrease.
In Asia the epidemic started later, but exploded
during the last decade. The aggressive prevention
programs in Thailand and Cambodia showed that
reduction of transmission is possible. The infection
level is not above 3 to 4% in pregnant women in any
Asian country, but there is big concern that because
of the present high risk behavior outbreaks can be
expected. At this moment the spread of HIV is
augmenting especially in South and South East Asia.
In Latin America and the Caribbean the epidemic is
also spreading fast. The Caribbean being the second
most affected region in the world after Sub-Saharan
Africa. In Haiti, the most affected country of this
region, the prevalence is 6% in adults. The epidemic
there was recognized at the same time as the first
cases in the US, probably in relation with the sex
tourism of some homosexual men.
In South America, Brazil, a widely affected country,
took a leading role in efforts to fight HIV by producing
and providing free generic drugs and conducting large
education programs.
Eastern European countries show a big rise in
prevalence especially through IV drug use. Probably
the spread in this region is the fastest in the world.
The social and economic consequences in the
developing world are already being felt widely not only
in the health care system but also in education,
industry, agriculture, transport, human resources and
the economy in general. It’s difficult to overview all the
consequences of this dramatic epidemic.
Treatment of the disease
In the beginning of the pandemic, the first therapeutic
options were treatment of opportunistic infections.
In 1987 the FDA approved the first antiretroviral
medication zidovudine, AZT, which gave hope (18), 
but after a year it became clear that resistance
developed (19, 20) and it proved to have only a
temporary effect. In the early nineties several new
drugs, with a different action than AZT were produced.
In 1995, a new class of drugs was discovered: the
protease inhibitors PI. The great breakthrough came in
the same year when studies showed that using a
00002-E-1 – 1 December 2003
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Fig. 1 -  Adults and children estimated to be living with HIV/AIDS at the end of 2003.
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combination of three different drugs, viral replication
could be suppressed for a long period (21, 22). This
strategy, called HAART: Highly Active Antiretroviral
Therapy, became the norm in the industrialized world
and significantly influenced the mortality and morbidity.
In spite of this effective strategy, only 7% of the
patients in need of treatment were receiving it
thoughout the world in 2003. Cheaper generic drugs
are being produced by different countries in order to
combat the biggest killer in the world. The WHO has
planned to treat 3 million people living with HIV/AIDS
with antiretroviral medication in the developing world
by the end of 2005; the 3-by-5 project (23).
Knowledge of the immune system and the virus
Scientists worldwide are searching for a better
understanding of the immune system. The HIV
pandemic led to an explosion in scientific virological
and immunological studies. Destruction of the immune
system is being understood better and better, while no
cure has yet been found. Studying the differences
between the immune system of non human primates
and humans can help us to understand why the virus
is pathogenic in humans without causing devastating
effects in the respective natural hosts. In the natural
host the virus doesn’t cause immune activation.
Future therapeutic strategies could try to temper the
activation of the immune system. Another point of
study is the genetic dr ift of the HIV virus. The
existence of different genetic subtypes, with their
respective geographical distribution restricts the
possibilities for future vaccination strategies. The HIV
virus, showing a fast evolution through continuous
mutation, evades the specific immune answer, which
always seems a step behind. Moreover the capacity
for mutation is the cause of emerging drug resistance,
which is of great concern. In the western world, where
a lot of different drugs are used, the virus is subjected
to enormous genetic pressure. And in the developing
world fear exists that the efficacy of the limited drug
reper toire wil l  fast be exhausted because of
transmission of drug resistant viruses.
Current data
It is estimated that today 34-46 million people are
living with HIV/AIDS, 2.5 million of them are under the
age of 15 years. Last year 3 million people died of
AIDS and 5 million people became infected (Tab. II). In
the near future it is expected that even more people
will die of AIDS. In 2003 it was estimated that every
day 14,000 people become infected with the virus and
over 8,200 people died of AIDS every day. The
situation is most dramatic in Sub-Saharan-Africa
where two thirds of the people infected with HIV are
living. One in twelve adults is infected in this region!
95% of the people living with HIV/AIDS are living in
the developing world. It is expected that 6 million
people will die in the near future if they don’t receive
treatment. Life expectancy at birth has declined with
15 to 20 years in the most heavily affected countries.
From the beginning of the pandemic until now it is
estimated that 22 million people have already died of
AIDS. 14 million children became orphans due to
AIDS, meaning they lost one or both parents from
AIDS, before the age of 15. It is estimated that by
2010, at least 44 million children will have lost one or
both parents due to AIDS.
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TABLE II - GLOBAL ESTIMATES OF HIV INFECTION AND AIDS IN ADULTS AND CHILDREN (END OF 2003)





New HIV infections in 2003 5.0 million
Deaths due to HIV/AIDS in 2003 3.2 million
Total deaths from AIDS, 1982-2003 23.0 million
Children orphaned by AIDS 14.8 million
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2.2 EVOLUTION OF THE HIV INFECTION  
 
2.2.1 Clinical disease progression 
During the course of an HIV-infection, distinct clinical stages can be recognised. Immediately 
after HIV-infection, 40 to 90% of the patients7,8 experience symptoms such as fever, sore 
throat, nausea, diarrhoea, rash, myalgy, headache,… Because of the aspecificity of these 
symptoms, the disease often goes undiagnosed. The severity of this acute retroviral syndrome 
(ARS) differs from individual to individual. (This is an important factor in predicting the final 
clinical outcome 9, 10.)  
The acute infection stage, which can last for several weeks, is followed by an asymptomatic 
phase known as the period of ‘clinical latency’11, 12. This latency can last for several years 
(with an average of 10 years in the western world). During the asymptomatic stage, the risk 
for infections in the HIV-infected patient is similar to that of the general population, despite 
the appearance of enlarged lymph nodes.  
The transition to the late stage of the disease is marked by constitutional symptoms such as 
weight loss, fatigue, fever, sweats and some dermatological infections…  
The latest stage or the Acquired Immune Deficiency Syndrome (AIDS) is characterised not 
only by the occurrence of opportunistic infections specifically observed in severe immune 
deficient patients but also by central nervous symptoms caused by HIV and by particular 
cancers (WHO/CDC classification 2005) (Fig. 2).   
 
2.2.2 Virological aspects of HIV infection 
 
Viral load 
In the early phase of the HIV-infection, viral RNA concentrations in plasma reach peak levels 
of 105-108 copies/ml 13. This peak viral load (VL) is observed within a few weeks following 
the onset of infection.  
After 6 to12 months, steady-state plasma viral RNA levels are established, which are lower 
than those found during acute infection (~103-104 copies/ml plasma) 14. These steady state 
plasma levels are a good measure of the rate by which the HIV disease advances 15, 16.  
Plasma VL steadily augments as the disease progresses, ultimately reaching levels above 106 





The HIV transmission generally occurs by only a restricted number of viruses 17, 18, explaining 
the low viral diversity early in infection 19. However, the viral diversity increases fast 
thereafter, due to the high mutation and replication rate of the virus. The high mutation rate of 
3x10–5 base pairs per replication cycle 20 results from the lack of proofreading activity of the 
Reverse Transcriptase (RT) 21. The combination of a high mutation rate and a high replication 
rate (108-1010 viral particles per day) 22 generates a huge diversity. All sorts of pressure result 
in a fast selection of escape viruses. One type of selective pressure is exerted by ART. Low 
adherence to the therapy and inefficient ART lead to a fast selection of drug resistant viruses. 
Another type of pressure is exerted by the immune system. Early in the HIV-infection, 
immune escape viruses are selected 23, 24. A third type of selective pressure is due to the 
specific micro-environment at the site of viral replication. Combined with a distinct 
distribution of target cells in tissues 26 this leads to localised divergence and 
compartmentalisation 25.  
Recombination is another mechanism explaining the viral diversity in the HIV-infected 
individual. Superinfection (the sequential infection from two sources), or concomitant 
infection explains co-infection with distinct HIV-subtypes. Inter- and intra-subtype genetic 
recombination occurs. The recombination rate will be higher intrasubtype compared to 
intersubtype 27-29, while influence on diversity will be of more importance when 
recombination occurs intersubtype.     
 
Latency 
The major impediment to the total eradication of HIV is the establishment of a viral reservoir. 
This already occurs in the first days after infection 30. In the transcriptionally silent condition, 
HIV evades recognition by the immune system and targeting by ART. 
When a cell becomes infected with HIV, the viral genome undergoes reverse transcription. 
The subsequently transcribed DNA either is inserted into the human genome (integrated DNA 
= proviral DNA) or remains non-integrated 31. The non-integrated form is unstable and 
decreases very fast under ART 32. On the other hand, the decay rate of the more stable 
integrated provirus under HAART is very low.  
The integration-site is located preferentially in active genes 33 and is supposed not only to 
determine the efficacy of subsequent viral replication but also to play a role in the latency 
status of the HIV-virus 34.  
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The resting memory CD4 T cells harbour the greatest part of the actually known HIV-
reservoir. Latency in these cells is supposed to arise from HIV-infection of activated CD4 T 
cells at the moment that these cells are turning to the resting state. Other cells that contribute 
to the latent HIV-reservoir are macrophages 25, monocytes 35, dentritic cells 25, 36, γδ T cells 37 
and natural killer (NK) cells 38. The contribution of all these different cell types to the latent 
pool, depends on the half-live of these cells, their cellular activity, sensitivity to apoptosis and 
their distribution in the distinct tissues (as the brain 39, testes, kidneys, …). The peripheral 
blood cells are the best accessible and most frequently studied HIV-infected cells, although, 
they are supposed to constitute only a minor fraction of the total HIV-reservoir. 
 
 
Clinical, virological and immunological evolution of an HIV-infection 
 
 
ig. 2: The distinct phases of the HIV-infection; clinical, viral load and CD4 T cell number 
er.com/encyclopedia/HIV). 
.2.3 Immunological evolution 
 a crucial role in the immune system are paralysed from the 
early start of HIV-infection. The adaptive as well as the innate immune system and the links 








































































A major number of cells that play
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 Adaptive immune system 
CD4/CD8 T cell ratio and CD4 T cell counts 
lready early in the HIV-infection, the number of CD4 T cells, constituting the main marker 
profoundly decreased. At the same time CD8 T cells expand, 
r the course of the HIV-infection 11. When CD4 
s as when to start preventive 
  
 
Fig. 3: Mechanisms contributing to the total number of blood CD4 T cells  
 
A
of disease progression, is 
leading to an inverted CD4/CD8 T cell ratio.  
After the early stage there is a spontaneous but incomplete recovery of CD4 T cells (Fig. 2), 
while the CD4/CD8 T cell ratio generally remains inverted.  
Afterwards, CD4 T cells gradually decline ove
T cells fall below a critical level (<200 cells/µl blood or <14% of blood lymphocytes), the risk 
to develop OI’s increases considerably. Clinical decision
treatment for OI’s and/or ART will strongly be influenced by the CD4 T cell count.   
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The progressive loss of the CD4 T cells is the result of the imbalance between the clearance 
and the renewal of those cells. This implies that the production of the CD4 T cells, which is in 
the order of 2x109 cells per day (in HIV-infection), is exceeded by its destruction. CD4 T cell 
destruction is caused by direct cytotoxicity of HIV and by apoptosis of HIV-infected and 
uninfected CD4 T cells.  
In vitro HIV-infection is associated with apoptosis of T cells and T cell lines 40-42. The 
activation state of the host cell probably influences its sensitivity to direct viral toxicity, as 
activated cells faster undergo apoptosis. Direct viral toxicity, however, is probably not the 
main reason for the CD4 T cell decline, as the number of HIV-infected cells is too low (in the 
order of 1/1000 to 1/8000) to explain the observed cell death and as only a minor fraction of 
the apoptotic cells is physically infected by HIV. Apoptosis has indeed been shown to occur 
especially in bystander cells 43 and less in productively HIV-infected cells 44, 45.  
Besides direct viral cytotoxicity, cell death can be explained by apoptosis induced by viral 
plasma proteins. In vitro, the interaction of the viral gp120 envelope protein with CD4 has 
been shown to impair lymphocyte function 46 and to prime T cells for programmed cell death 
CD) 47. Subsequent T cell receptor (TCR) engagement is sufficient to induce apoptosis. 
lternatively, if the HIV-infected cells are already activated, binding of gp120 to the 
lasma proteins have been reported to play a role in inducing cell death 48.   




CD4/CXCR4 molecules induces cell death. In addition, not only gp120, but also other HIV 
p
Apoptosis of lymphocytes also results from continuous immune activation as described in 
chronic infections with cytomegalovirus, Epstein Barr virus and varicella zoster. This 
physiological apoptosis is called activation induced cell death (AICD) 49, 50. AICD is the 
regulatory mechanism necessary in order to maintain the equilibrium in the repertoire of 
immune cells after antige
death can be attributed to AICD 51, 52.   
The immune response against HIV is as well responsible for the induction of cell death. This 
is mediated by cytotoxic T lymphocytes (CTL’s) and Natural Killer cells (NK cells) which 
lyse HIV-infected cells.  
Several scientists suggest that auto-immune mechanisms, provoked by HIV contribute to a 
progressive decline in CD4 T cell count and cause progression from HIV-infection to AIDS53.  
In addition to the enhanced destruction of CD4 T cells, also the replenishm  of those cells is 
severely affected by HIV-infection because of diminished thymic output. HIV-infection 
causes a profound reduction in precursor proliferation of thymocytes 54, leading to a serious 
limitation in CD4 T cell regeneration 55.  
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Trapping of CD4 T cells in the lymph nodes also contributes to the decline of their number in 
the blood 56. 
 
CD8 T cells, cytotoxic T cells (CTL) 
In the acute HIV-infection, a crucial role is attributed to HIV-specific CTL’s. The clonal 
expansion of these CTL’s is supposed to be responsible for the decline in plasma peak VL 57 
as it occurs simultaneous. Studies in non-human primates also provide arguments for the 
pivotal role of these CTL’s as depletion of CTL’s results in an uncontrolled viral replication 
and a fast progression to AIDS 58, 59. The antiviral effect of CTL’s relies on their possibility to 
lyse HIV-infected cells and to release soluble antiviral factors. 
DS is seen (Fig. 4).  
vation that over the disease course different HIV 
infection and are shown to be related with suppressed VL 61-63.      
nother mechanism that explains the persistence of HIV replication despite the presence of 
 of tolerance and clonal exhaustion because of the 
 
Despite the continuous presence of high amounts of HIV-specific CTL’s throughout the HIV 
disease, progression to AI
It is suggested that the efficacy of the CTL’s decreases after the acute phase of HIV-infection 
as a result of the depletion of sustaining HIV-specific CD4 T cells (Fig. 4; 1).  
In addition, the fast occurrence of immune escape HIV variants is responsible for the loss of 
efficient CTL immune responses 23, 24, 60(Fig. 4; 2). Antigen presentation as well as immune 
recognition can be affected by these mutations which diminish the sensitivity of HIV-infected 
cells to CTL-mediated lysis. The obser
peptides are recognised is in line with this hypothesis. Tat and Rev are especially targeted 
early in HIV-
A
HIV-specific CTL’s, is the induction
extremely high concentrations of antigen 64, 65 (Fig. 4; 3).   
Deficient co-stimulation, because of an HIV-induced decreased expression of co-stimulatory 














Causes of CTL dysfunction  
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Fig. 4: Different mechanisms that contribute to the dysfunction of CTL’s 
 
 
Innate Immune system 
Also the cells of the innate immune system are seriously affected by the HIV virus. The 
immune dysfunction caused by HIV, in Natural Killer (NK) cells, NKT cells, monocytes, 
macrophages and Dendritic Cells (DC) (all responsible for the innate immune response), is 
characterised by serious functional impairment in addition to reduced cell numbers. NK cells 
are impaired in their cytotoxic activity, which can be explained by a shift in cell subsets; HIV 
causes an expansion of dysfunctional NK cells (CD56-/CD16+), which have an upregulated 
expression of inhibitory NK receptors and a downregulated expression of cytotoxic 
receptors66. Those cells also have an impaired secretion of antiviral cytotoxic cytokines. On 
the other hand HIV causes a downregulation in HLA class I A and B expression in the 
infected cells 67, which further increases their escape from NK cell killing. The NKT subset 
mory CTL
Cell death
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expressing CD4, is seriously depleted in HIV infection 68. Monocytes and macrophages can 
become infected by HIV as they express CD4 and CCR5 coreceptor. Those cells, together 
with DC’s, are spreading the virus as a Trojan horse to the different organs 69. DC’s are 
impaired in their stimulation of T cells, probably because of a diminished expression of 
costimulatory cules and a block in their maturation 70.        
   
2.2.4 Inter-individual differences  
Disease progression varies strongly among HIV-infected individuals. A small subset of HIV-
infected individuals (1%) is able to maintain high and stable CD4 T cell counts together with 
low to undetectable plasma VL for more than 10-15 years in the absence of ART 71-73. These 
patients are called Long-Term Non-Progressors (LTNP). On the other hand, very fast 
progression with evolution to AIDS in several months also has been described 74, 75. In 
general, in the western world, HIV-infected individuals are without therapy, progressing to 
AIDS in a mean period of 10 years.  
Factors influencing the rate of disease progression in HIV infection vary greatly among 
individuals and are still poorly defined. Yet, HIV-specific CD4 helper and effector T cell 
responses are consistently found in LTNP 73. Certainly viral as well as host dependent 
mechanisms contribute to the rate of disease progression. Among viral factors deletions in 
d Nef and insertion 
 Vpu genes 77, have been related with slow or non-progression . In addition, host dependent 
echanisms are the expression of certain HLA class I haplotypes 78-80, expression of the Δ32 
r 81 or other co-receptor polymorphisms 82 and certain cytokine and 
 mole




cytokine receptor specificities 83.    
Understanding the factors related with better outcome of the HIV-infection will improve our 










2.3 INFLUENCE OF HAART ON CLINICAL DISEASE PROGRESSION, VIRAL 
RESERVOIRS AND IMMUNE FUNCTION 
 
Action sites of antiretroviral drugs 
 
 
Fig. 5: Viral replication and action sites of different antiretroviral drug classes (from: 
http://webs.wichita.edu/mschneegurt/biol103/lecture15/hiv_cycle_drugs_best.jpg). 
 
2.3.1 Influence of HAART on clinical disease progression  
The clinical impact of HAART strongly depends on the stage of the disease at which HAART 
 started. It is obvious that in the ‘clinical latency’ phase no immediate clinical benefit will be 
een. Moreover, adverse effects of ART can worsen the patient’s quality of life in the short 
nd long term. Depending on the specific antiretroviral drugs complications are 
podystrophy, glucose intolerance, allergies, gastro-intestinal intolerance and neurological 
conveniences. Those side effects are responsible for a large proportion of the 
ospitalisations among the HIV infected patients.  
he start of HAART late in the course of the HIV disease, on the other hand, can be followed 









symptoms of AIDS, they will first receive treatment for the OI and ART will be started later. 
The effect of this combined treatment can be very spectacular and is known as the ‘Lazarus 
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Syndrome’. Patients nearly dying on admission in the hospital, are able to return to work and 
 lead a normal life after a period of treatment.  
After the instauration of HAART, however, some patients are clinically deteriorating despite 
decreasing VL and rising CD4 T cells. Side effects of medication but also unrecognised OI’s 
or auto-immune diseases can cause the new or aggravated symptoms. Progression to AIDS 
can easily occur in this late stage disease even after instauration of HAART. The CD4 T cell 
count at initiation of therapy is the dominant prognostic factor in this progression to AIDS 84.  
Another possible cause of clinical deterioration is paradoxically due to the immune recovery 
on ART. Pathogens, previously present in the tissue but unable to cause an immune reaction 
because of the profound immunologic failure, are now able to provoke a severe inflammatory 
response. This phenomenon is known as the immune reconstitution inflammatory syndrome 
(IRIS). The inflammatory reaction can be extremely strong, leading to death (for example 
through rise of intracranial pressure) or irreversible sequelae as for example blindness. HIV-
infected individuals at risk for IRIS are those with previous apparent or sub-clinical OI’s. The 
pathogens most frequently associated with IRIS are cytomegalovirus, Mycobacterium 
 and high 
lasma VL at the time of starting HAART 85. IRIS is associated with a strong decrease in 
T, starting HAART within the 
ate stage HIV-infection is able to prevent 
 to undetectable levels (<50 HIV copies/ml 
to
tuberculosis, Mycobacterium avium, Cryptococcus neoformans, hepatitis B and C and herpes 
zoster. Factors, related with a high occurrence of IRIS are low CD4 T cell count
p
plasma VL in the first 3 months after instauration of HAAR
first 30 days after initiating treatment for an OI and the fact of being ARV naïve before 
starting HAART 86. Other studies found that a higher rise in CD4 T cell percentage 87 and in 
CD4/CD8 T cell ratio 88 was especially correlated with a higher incidence of IRIS.  
It is difficult to distinguish between the intimately linked inflammation and active infection as 
the cause of clinical deterioration. Usually non steroidal anti-inflammatory drugs as well as 
corticosteroids eventually combined with antimicrobial therapy provide relief 89, 90.  
It is not known if a certain treatment strategy in l
IRIS. No consensus exists about the management of HIV-infected individuals presenting with 
severe immune deficiency and OI’s. Therapeutic decisions are taken case by case, relying on 
clinical presentation, drug related adverse effects, pill burden and the patient’s choice.  
 
2.3.2 Influence of HAART on viral load, latency and resistance  
HAART is generally able to suppress plasma VL
plasma). The time period after which this undetectable VL is reached is longer in patients 
with a high plasma VL (>105 log copies/ml) at the start of HAART.  
 28
Despite prolonged periods of efficient ART resulting in long term undetectable plasma VL, 
the latent HIV pool decreases very slowly. The half-life time of memory CD4 T cells, which 
harbour the greatest part of the latent HIV reservoir in the blood, is shown to be at least 44 
months 91, 92. Immune intervention (e.g. with IL-2) 93, 94 and HAART intensification 95 can 
augment the proviral decay rates. Proviral decay rates are also higher in treated acute HIV-
infection 96, 97.  
Sustained low level HIV replication is supposed to contribute to the containment or even the 
expansion of the HIV proviral reservoir 25. The frequency of detectable viral blips (>50 HIV 
copies/ml) was found to be two times higher in HIV-infected individuals treated during 
chronic infection compared to those treated during acute infection 98.  
Problems of ARV drug resistance, emerging fast during periods of non-compliance or sub-
optimal HAART, compromise the clinical benefits related to ART. Genotyping, detecting 
specific resistance-linked mutations, is the most frequently used method to detect drug 
resistance. A large number of mutations associated with resistance to the currently used ARV 
drugs are identified 99. These mutations generally emerge in a step-wise manner with a 
cumulative influence on the sensitivity to the ARV drugs. Different algorithms are used to 
predict phenotypical resistance based on the observed genotype (Stanford University, REGA 
Institute). The results of these predictions are guiding the clinicians in their choice for 
he timing of HAART intervention may be a key factor in determining the extent of possible 
r with a CD4 T cell count 
rlier in the HIV disease 
effective HAART combinations.  
 
2.3.3 Immune recovery under HAART 
Many cells that mediate important immune functions are affected by HIV: CD4 T cells, HIV-
specific CD4 and CD8 T cells, γδ T cells, dendritic cells (DCs), IFNα producing Antigen 
Presenting cells (APC’s), NK cells, Natural Killer T (NKT) cells,… These impaired immune 
functions cannot always recover with HAART.  
T
immune restoration. There is a consensus that patients with AIDS o
<200 cells/µl blood should receive HAART. Recent guidelines recommend now intervention 
with HAART at 350 CD4 T cells/µl blood. This is in line with studies demonstrating that the 
immune recovery will be more pronounced if therapy is started ea
course 100-102. However, studies have shown that even with extremely severe immune 
deficiency significant increases in CD4 T cell count could be obtained with HAART in 
combination with IL-2 103.  
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When the mean recovery of CD4 T cells is studied, a biphasic process is observed 104. In the 
first year, the number of memory CD4 T cells increases rapidly, which is explained by a 
ms responsible for this 
e answer, analysed by the T cell receptor (TCR) repertoire, 
 enhanced for CD8 T cells in HAART treated acute and chronic HIV-infection, while for 
 HAART treated acute infection 112.   
IV-infected patients starting HAART and is 
redistribution of CD4 T cells from the periphery, especially from the lymph nodes to the 
blood 105, 106. This is followed by a slow increase in naïve CD4 T cells, which continues for 2 
to 3 years after instauration of HAART 107. Therapy in early HIV-infection, however, can 
result in an immediate rise in naïve CD4 T cells 108. When mechanis
increase are further investigated a reduction in direct viral cytotoxicity and indirect apoptosis 
with an increased thymic output is expected. Al-Harthi et al. reported that a significant 
reduction of apoptosis because of HAART could only be found in HIV-infected patients who 
had >500 CD4 T cells/µl blood at the start of treatment 109, 110. Naïve CD4 T cells, rising after 
the instauration of HAART are supposed to proceed from the thymus. T cell receptor excision 
circles (TREC’s), a marker for recent thymic immigrants (RTE), are rising because of 
HAART even irrespective of HIV-infection 111. A longer thymocyte survival is suggested as 
explanation. Thymus volume is shown to increase in some patients after the instauration of 
ART. Also diversity of the immun
is
CD4 T cells amelioration was only seen in
Some patients fail to exhibit a marked increase in CD4 T cells despite a suppression of their 
VL to undetectable levels in response to HAART. The opposite, an increase in CD4 T cells 
without a total viral suppression, is also observed. This discordance between virological and 
immunological responses is seen in 5-27 % of H
associated with a poor clinical outcome 113. Thymus failure 114 or sustained apoptosis 115 are 
proposed to be the reason of failing immune recovery. PI-containing HAART regimens are 
associated with better immune recovery 116. Virological failure with immunological response 
can be explained by resistance 117 and adherence problems 118 but is also found associated 
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CHAPTER III: AIMS 
 
 
Although the benefit of HAART on HIV-related morbidity and mortality is proven, the 
current ART is unable to eradicate HIV. Moreover, short and long term drug toxicity, 
adherence problems because of drug intake fatigue and the resulting resistance problems all 
compromise the efficacy of HAART.  
For the optimal use of HAART, a lot of questions remain to be elucidated. When is the 
optimal time to start HAART? What are the risks and benefits of a temporary HAART 
regimen in early HIV-infection? Can HAART, started early in HIV-infection, induce a status 
of long-term non-progression? How long should temporary HAART in early HIV-infection be 
given? Is recycling of ARV drugs possible after resistance formation?  
To answer those questions we studied the effect of HAART in different cohorts of HIV-
infected individuals.  
 
1) As an introduction to the different sub-studies that are presented in this work, we assessed 
in article 1 the global impact of the first decade of HAART on the AIDS epidemic, with 
special emphasis on the differences between the western and the developing world.  
 
2) From viral as well as immunological point of view, treatment in acute HIV-infection can be 
very useful. Early treatment of HIV-infection restricts viral diversity and spread and the 
amount of latently HIV-infected cells. This strategy also preserves HIV-specific CD4 T cells 
and maintains a larger and broader CD4 T cell repertoire. Most of the studies showing a better 
immune recovery or a lower burden in viral HIV reservoir with early ART are assessing those 
factors while patients are still on therapy. As HAART is associated with diverse side effects 
and risk for drug resistance, it is important to evaluate whether temporary treatment can 
change the HIV disease evolution.  
In article 2, we investigated the benefit of HAART started early after HIV-infection. VL, CD4 
T cell count and HIV-specific immunity were analysed longitudinal after treatment 
interruption in a group of 40 patients. A cohort of 28 acute HIV-infected patients that 
remained untreated was followed as a control group.  
  
3) A large proportion of HIV-infected patients, however, first consults in the late stage of the 
HIV disease. In article 3, the start of HAART in late stage HIV-infection was investigated. 
 41
The clinical consequences of this strategy are illustrated by a case report of a tuberculosis 
(TB)/HIV co-infected patient suffering from IRIS.   
 
4+5) Although the theoretical ultimate goal of therapy is the total clearance of HIV from its 
host, it is more and more clear that this goal will not be reached in HIV-infection with the 
current HAART. This is mainly due to two factors: (1) the development of ARV drug 
resistance and (2) the presence of a long living HIV reservoir. ARV medication, exerting its 
action by blocking viral replication, can not target latent HIV as no replication takes place. 
The combination of resistance and latency compromising the efficacy of HAART, is 
addressed in articles 4 and 5. A cohort of patients harbouring resistant HIV was switched to 
an efficient HAART regimen which suppressed their plasma VL to undetectable levels for 
several years (mean: 59 months). Genotyping of pro-viral reservoir in those patients, assessed 
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Abstract: We investigated the long-term benefit of early temporary antiretroviral therapy in 
HIV-1 infection. Sixty-eight recently infected individuals were selected of whom forty initiated 
antiretroviral therapy within the first 6 months of infection. Twenty eight patients remained 
untreated. Eight patients were excluded for further analysis because they did not achieve an 
undetectable viral load. The remaining 32 patients stayed on treatment for a mean period of 17,3 
months. Blood samples were collected regularly before, during and after treatment, for viral load 
(VL) determination and CD4 T cell count. HIV specific CD8 and CD4 T cells, producing IFN-γ 
in response to overlapping HIV peptides, were measured in 23 individuals (13 treated and 10 
untreated). The evolution of the different parameters in treated and untreated individuals was 
compared, after therapy interruption and infection respectively.   
Over the 3 years of treatment free follow-up a trend towards lower VL and higher CD4 T cell 
count was seen in the treated patients compared to the untreated individuals. No loss of HIV-
specific immune cells because of treatment was observed. In conclusion, our results indicate that 
temporary treatment early after infection can result in a delay in disease evolution that extends 
the strict time on therapy.  
 















Acute HIV-1 infection is characterized by an extensive viral replication reaching levels of over 
106copies HIV-1 RNA/ml. The spontaneous decrease of viral load after the initial burst 1 is 
mainly attributed to the development of a specific immune response 2, 3, in combination with a 
profound loss of target CD4 T cells. Cytotoxic CD8 T cells (CTL’s), supported in their function 
by CD4 T cells, are thought to play a pivotal role in the early immune response as their expansion 
coincides with the decrease in plasma VL. In addition, studies in CD8 T cell depleted macaques 
demonstrated an uncontrolled replication of the virus and an accelerated clinical progress 4, 5. The 
efficacy of the CD8 T cell responses, however, seems strongly diminished in the later stages of 
the infection, as observations show that disease progresses despite the presence of high numbers 
of CTL’s. The decrease of sustaining CD4 T cells and the selection of immune escape mutants 
are possible explanations for the failure of the CTL’s.  
The possible benefit of treating patients during acute infection is a matter of controverse. 
Although studies showed that early ART could preserve HIV-specific immunity 6-8, side effects 
of the current treatment protocols such as lipodystrophy, glucose intolerance, allergies, gastro-
intestinal intolerance and neurological inconveniences limit their long term use.  Current 
guidelines therefore recommend the initiation of ART only in those patients in whom CD4 counts 
are indicative for a fast progression towards AIDS 9.   
Only few studies have evaluated the long-term effect of temporary early treatment on biological 
parameters as CD4 T cell count and VL. Although this approach might allow the preservation of 
HIV-specific CD4 T cell responses, and possibly induce a long term immune control, fear exists 
that after stopping the treatment, viral rebound soon abolishes the possible benefits.  
We studied 68 patients with an acute HIV-1 infection. Forty patients were temporary treated 
within the first six months of their infection, with individual adapted ART. Thirty two were able 
to reach undetectable viral load levels and were included for further analysis. Longitudinal 
analysis for VL and CD4 T cell count were performed and the results were compared for the 32 
treated and 28 untreated individuals. In 23 patients, 13 treated and 10 untreated, also the presence 
of HIV specific IFN-γ producing CD8 and CD4 T cells was examined. 
 
Materials and Methods 
 
Patient recruitment  
Sixty-eight adult individuals with a documented acute HIV-infection were included in the study. 
Sixty-six were Caucasian and sixty-four were men. Seventeen had been tested positive for 
syphilis, one patient had an active hepatitis B infection and 3 had active hepatitis C. Baseline 
clinical characteristics were comparable in both groups. Early infection was attributed to the 
individuals with either a documented HIV seroconversion, an isolated high risk exposure, an 
indeterminate western blot or an acute seroconversion syndrome. Forty patients were consulting 
the Aids reference Centre (ARC) in the first six months after the presumed infection date and 
were willing to participate in the study. They all received ART treatment. The ART combination 
was chosen on an individual basis. Twenty eight patients consulted the ARC later than six 
months after the presumed infection date and these patients were followed as untreated controls. 
The study was approved by the Ethical Committee of our institution and the participating patients 
signed the informed consent form. 
 
PBMC’s, CD4 T cell counts, HIV-1 levels:  
At each visit CD4 T cells numbers were determined by flow cytometry using the FACScan 
cytofluorometer and the Cellquest software (Beckton Dickinson Mountain View, California, 
USA). CD4 T cells numbers were expressed as cells per microliter whole blood. Plasma HIV-1 
was measured using the ultrasensitive Amplicor HIV-1 Monitor test (Roche Diagnostic Systems) 
with a lower detection limit of 1,7 log10 copies/ml and a higher detection limit of 5,0 log10 
copies/ml. PBMC’s were recovered by centrifugation on Ficoll-Hypaque gradients and 
cryopreserved in 90% FCS and 10% DMSO. PBMC’s were thawed on the day of testing.  
 
Stimulation assay for HIV specific CD4 and CD8 lymphocytes 
PBMC’s were thawed and used in a stimulation assay as described 10. PBMC’s were suspended at 
106 /150 µl RPMI medium, together with co-stimulatory antibodies; anti-CD49d and anti-CD28, 
at a final concentration of 1µg/ml each. Cells were divided in a 96 well round bottom plate and 
peptides were added at a concentration of 2µg/ml. The peptides were obtained from the NIBSC 
centralized Facility for AIDS reagents (UK). The peptides used were 20-mers spanning the rev, 
tat and p24 region and 15-mers spanning the p17 region of HIV-1 type B. As negative control, 
only co-stimulatory antibodies without peptides were added. As positive control we used SEB 
2µg/ml. 10µg/ml BFA was added to each well. The final volume was 200µl/well. Cells were left 
at 37°C in a humidified 7% CO2 incubator for 5 hours. After this incubation, cells were placed 
overnight in a refrigerator, protected from light. Subsequently, cell surfaces were stained with 
CD4-PerCP, CD3-APC and CD8-PE (Becton Dickinson). Cells were permeabilised with 
cytofix/cytoperm (BD) and additionally stained intracellular for IFN-γ-FITC (BD). Acquisition 
was done with the FACScalibur; 500.000 cells per test were acquired. Frequencies of IFN-γ 
producing cells were reported after subtraction of the frequencies in medium controls. Tests were 
done at least in two-fold and mean results were taken for presentation.  
 
Statistical analysis 
Statitistical analysis was performed using the program SPSS 12.0 for windows. The Mann 
Whitney test was used for analyzing differences between groups. For longitudinal tests in one 
group the Wilcoxon rank test was chosen. Kaplan Meier survival curve was used together with 





Of the 68 individuals with acute HIV-1 infection that were selected, 28 remained untreated. 
Treatment was initiated within 6 months after the onset of infection in 40. Eight of them did not 
reach undetectable viral load levels due to non-compliance (in 7) or side effects (in 1) and the 
therapy in these patients was stopped. Final analysis was performed on the remaining 32 treated 
(T) and the 28 untreated patients (UT). The treatment-free follow-up time was counted from the 
treatment interruption in the patients receiving therapy while for the patients who remained 
untreated the follow-up time was counted from the presumed infection date. The mean treatment 
free follow-up period was 34 months (5-87 months). The mean age at infection and the baseline 
CD4 T cell counts were comparable in both groups (UT: 34 years versus T: 36 years; p=0.744; 
UT: 506 versus T: 492 cells/µl; p=0.578), but a significantly lower mean VL was observed in the 
untreated individuals (p<0,001) (see Table I).  
 
The effect of ART on viral load 
Antiretroviral therapy suppressed plasma viral load to undetectable levels in the 32 patients after 
a mean period of less than four months. After one year of treatment free follow-up, the mean viral 
load in the patients who received treatment was lower than the mean viral load in the treatment 
naïve patients (3,95 log versus 4,42 log; p=0.060). Lower viral loads in the treated group were 
also observed after 2 and 3 years of follow-up, though differences were not statistically 
significant (respectively 3,86 log and 4,30 log after 2 years; p=0,108; 3,63 log and 4,05 log after 
3 years; p=0.172) (see Table I).  
The Kaplan Meier curve (not shown) illustrates the evolution of the VL in the two groups. An 
endpoint VL of 55 000 copies/ml was chosen. The treated patients were able to suppress their 
viral load to below this endpoint for a significant longer time compared to the treatment naïve 
patients (Log Rank: 0,027).  
Detailed observation of the evolution of the viral load after treatment cessation in the different 
patients revealed different patterns. In part of the patients, a peak of virus replication followed by 
a relative suppression was observed, others showed a viral rebound without any subsequent 
control and in others no peak levels but a slow continuous increase of the viral load over time 
was seen. In 2 treated patients VL remained extremely low after treatment interruption (less than 
2,00 log). In one of them, the viral load even remained undetectable during the whole follow-up 
period of 18 months. 
 
The effect of ART on CD4 T cell count  
The use of ART during acute infection resulted in a mean increase of 332 CD4 T cells/µl as 
compared to the pretreatment baseline value (p<0.001). One year after treatment interruption the 
mean CD4 T cell count in the treated group was 666 cells/µl compared to 490 cells/µl in the 
treatment naïve group one year after infection  (p=0.087). After two years the mean CD4 T cell 
counts were respectively 569 and 488 (p=0.500). After 3 years CD4 T cell counts were 708 and 
505 respectively (p=0.010) (table I).   
We observed an overall association between a low baseline CD4 T cell count and a fast decline of 
CD4 cells after treatment interruption. However, in 5 of the 9 treated patients with baseline CD4 
T cell counts under 350 cells/µl, no drop below this level was observed during the treatment free 
follow-up of respectively 9, 30, 30, 33 and 50 months. 
 
The effect of ART on the IFN-γ-producing HIV-specific T cells. 
We determined the presence of HIV-1 specific CD8 and CD4 T cell IFN-γ reaction  respectively 
200 and 500 days after treatment interruption or infection (see fig 2). The mean HIV-specific 
CD8 reaction was not significantly different for both groups (3.35 x106 cells/l at 200 days and 
5.27 x106 cells/l at 500 days in the treated group; 1.20 x106 cells/l at 200 days and 1.95 x106 
cells/l at 500 days in the untreated group) (p=0.108 and p=0.099 respectively). An increase in 
reactivity over time was observed in both groups.  
Equally, no differences in HIV-specific CD4 T cell reactivity were seen, with a mean reactivity in 
the treated group of 0.77 x106 cells/l after 200 days and 0.69 x106 cells/l after 500 days and of 
0.41 x106 cells/l after 200 days and 0.63 x106 cells/l after 500 days in the treatment naïve group 
(p=0.23 and p=1). Immune reaction against p24 was observed most frequently in both groups. 
The second most frequently recognized peptide for CD8 T cell reactivity was p17. No relation 
could be found between the intensity of the CD8 T cell reaction and the viral load. The CD4 T 
cell analysis revealed generally lower percentages of cells producing IFN-γ, but in the 5 treated 
individuals with at least 2000 x 103 HIV-specific CD4 T cells/l, long term viral suppression was 
seen in 3 and temporary viral suppression in 2. In the untreated individuals CD4 T cell reactivity 
never reached levels of 2000 x 103 cells/l.  
In 2 of the treated individuals, CD8 T cell reaction to p17 epitopes arose after more than one year 
of treatment interruption. Moreover, in 2 other patients CD8 T cell reaction against respectively 
tat and rev arose after more than 3 years of interruption.  
 
The effect of ART on the need to restart treatment 
We also compared the number of patients in both the treated and the untreated group who 
reached the criteria to start or restart HAART. These criteria are a CD4 T cell count of less then 
350 cells/µl and/or a VL above 55 000 copies/ml. The period before reaching these criteria was 
significantly longer in the treated compared to the untreated individuals (Log Rank: 0,033) (Fig 
1). Of the 28 untreated patients with a follow-up of more than 2 years, 19 reached the criteria. 
Only 8 of them effectively started HAART. Of the 26 treated patients that were followed for 
more than 2 years after treatment interruption, only 10 reached the defined criteria. Five 
effectively restarted treatment.   
 
Discussion 
A relative and durable viral control in early HIV-1 infection has been seen following structured 
treatment interruptions (STI) 11, 12. The aim of these controlled on- and off-cycles of drug intake 
was to stimulate the immune system through natural vaccination. Results, however, were 
disappointing and the observation in some cases of drug resistant viral variants during the periods 
of therapy interruption 13 further tempered the enthusiasm. Also the risk of an extreme loss of 
CD4 T cells was described 14. Therefore most STI studies are actually stopped. The effect of one 
single short period of early antiretroviral therapy on the long term outcome of the infection on the 
other hand, is still rarely studied. Jansen et al. found that only one out of 5 temporary treated 
acute HIV-infected patients was able to maintain a viral control, one year after treatment 
interruption 7. Desquilbet et al. were not able to show a difference in VL, one year after treatment 
interruption, between 58 temporary treated patients and 116 patients that were never treated 15. 
Markowitz et al. also were not able to see a positive effect on the viral load set point, one year 
after an early antiretroviral treatment either or not combined with an adjunctive vaccine in 16 
individuals tested 16. The aim of the study presented here was to assess the influence of early but 
temporary treatment in a real-life setting. Despite the lack of restrictions according to the choice 
of the antiretroviral regimen or the duration of the treatment we were able to show that this 
approach is definitely not harmful for the patient or for the disease process and that it might even 
lead to a delayed disease process after therapy interruption.        
 
Sixty eight patients with a documented acute HIV-1 infection and for whom the presumed 
infection date could be defined, were studied. Patients willing to participate in the study were 
divided in two groups according to the time of their first consultation. Forty patients first visited 
the Aids Reference Centre of our hospital within 6 months after the presumed infection date and 
in these patients therapy was initiated. The drug regimen was individually adapted. Two patients, 
included during 1997, received bitherapy, the remaining 38 received a HAART regimen 
composed of 3 or 4 drugs. In the 32 analysed patients, ART was given for a mean period of 17,3 
months after which all medication was stopped. Twenty eight patients first visited the ARC 6 
months or later after the presumed infection time. These patients remained untreated. Viral load 
and CD4 T cell counts were determined in both groups as markers of disease progression. The 
baseline characteristics of both the treated and untreated group were comparable with exception 
of the baseline viral load that was significantly higher in the treated compared to the untreated 
group. This difference is most likely due to the fact that the baseline viral load sample for the 
treated individuals was obtained within 6 months of the presumed infection time, while in the 
untreated patients the interval between sampling and infection time was more than 6 months. 
Therefore most of the samples from the treated individuals have been collected during the peak of 
viral replication. The differences in baseline viral load between both groups however did not 
influence the findings and final conclusions of this work. 
 
The ART regimens were well tolerated in all but one patient. Seven patients were unable to reach 
an undetectable viral load within 6 months of therapy initiation. All 7 admitted bad adherence. 
For the remaining 32 patients therapy resulted in a fast drop of viral loads to below the limit of 
detection and a significant increase of the CD4 T cell count. After treatment interruption viral 
load rebounded in 31. One patient was able to maintain an undetectable viral load during the 
whole treatment free follow-up period of 18 months. Encouraging was that, despite the renewed 
virus replication and a decrease of the CD4 T cell count after the treatment stop, lower viral load 
levels and higher CD4 counts were consistently found after 1, 2 and 3 years follow up in the 
treated compared to the untreated patients, although, differences were not significant. Viral load 
levels and CD4 T cell numbers are generally accepted as good prognostic markers for disease 
progression 17-19. Our results are therefore indicative for a delay in disease progression in the 
treated individuals that extends beyond the strict on-treatment period.   
 
The number of patients included in the analysis for the 3 year follow-up time point was 
significantly reduced in both groups due to a drop out of those patients who needed to start or 
restart therapy and due the fact that for several patients the actual follow-up time did not exceed 2 
years. After 2 years of follow-up, the untreated patients achieved significantly faster the criteria 
to initiate medication compared to the treated patients. Therapy had to be initiated in 67,9% of 
the untreated patients, while reinitiation of therapy was needed in only 38,5% of the treated 
patient. The better outcome of the patients who received temporary treatment is also clearly 
illustrated in the Kaplan Meier curve in Fig 1, showing a significantly lower drop-out of patients 
because of viral loads exceeding 55 000 copies/ml in the treated group compared to the untreated 
group. We chose 55 000 copies/ml as cut-off value for the VL, as above this level HAART was 
often started 20.   
 
The difference in conclusion between our study and the former temporary treated patient cohorts 
reported, could be explained by our study design. We omitted patients not achieving undetectable 
viral load from further analysis. Only 1 patient in our study had adverse events that required 
interruption of treatment. The prevalence of adverse events was much higher in the study of 
Desquilbet et al. (12/58) 15, which could imply a higher risk for low level replication under 
treatment. However, we found the same mean VL set point after one year treatment interruption 
(3,95 log). In their study 22% were women, which were related with lower VL set points, while 
in our study only 9% were women. Their control patients were taken from another study cohort, 
at a much earlier time point (1989 ↔ 1996-2003), which could provoke a selection bias. 
Markowitz et al. 16 used vaccines, activating immune cells, and so inducing a higher amount of 
target cells. This could have a negative effect on the viral rebound. Jansen et al. studied only 5 
patients, so it is difficult to make general conclusions 7. 
 
We also analysed the cellular immune responses against several HIV peptides. In agreement with 
the results presented by others 6-8, 21-23, we were able to show that HIV-specific T cells are 
preserved through therapy in early HIV-infection. Besides, from the small cohort of patients that 
we studied we observed that the magnitude and the breadth of the CD4 and CD8 response in the 
treated patients after treatment interruption were superior to the untreated group. Absolute 
numbers of HIV-specific CD4 T cells exceeded 2 000 x 103 cells/l in all 5 patients with a post-
treatment suppression of the viral load; however, in 2 this suppression was only temporary. No 
relation between HIV-specific CD8 T cells and HIV-specific CD4 T cells or VL was seen. We 
observed that in most of the patients, HIV-specific CD8 T cell reaction is increasing over time 
after treatment interruption and that the response is broadening. Rising viral diversity can explain 
the broader T cell receptor recognition over time. It is also remarkable that even after a long time 
(> 3 years) of treatment interruption, new HIV peptides can be targeted. 
 
The improved outcome in the treated patients could be explained by efficient activation of a 
sufficient pool of HIV specific memory cells through viral rebound. Treating early in infection 
could also preserve other precious functions of the immune system 24. Restriction of viral 
diversity by early treatment might be beneficial for the immune response after treatment stop. A 
reduction of viral spread and proviral levels can have similar effects. 
 
The study presented here was performed on a relatively low number of patients. Although the 
results are promising, further analysis on larger patient populations is definitely needed to allow a 
better insight in the impact of temporary treatment on the disease evolution. Studies, aimed at 
elucidating the differences between those patients with a favourable outcome after treatment 
interruption and those with a bad outcome, will improve our understanding of the HIV 
pathogenesis and might guide the development of alternative intervention strategies. The ideal 
treatment period is actually unknown and needs further studies. In literature treatment in acute 
HIV infection varies between some weeks 8 and several years (3 years 16). Although the number 
of patients that we studied is small, our results pointed towards an improved outcome after longer 
treatment (more that 15 months) compared to shorter treatment (results not shown), but this 
observation definitely needs further evaluation. 
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Fig 1:  
Kaplan-Meier curve showing the percentage of patients who reach the criteria to start 
HAART; CD4 T cells <350 cells/ml and/or VL >55000 copies/µl, over time. Time is 
expressed in months. Log Rank between the T and UT group is 0,033.  
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Fig 2a Representative example of dot plots representing the reaction of CD3 CD8 T cells to 
the negative controle, to HIV-1 tat, rev, p17 and p24 peptides and to SEB.  
Fig 2b Cross-sectional absolute numbers (expressed in number x 103 cells/l) of HIV-specific 
CD8 and CD4 T cells at 200 and 500 days of therapy-free follow-up in treated (T) and 
untreated (UT) individuals. Means are shown with lines. 
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Table I 
UT group T group p values
(re)starting therapy in first 12 months of follow-up 6 3
(re)starting therapy after 12-24 months of follow-up 2 2
follow-up of less than 24 months 0 5
loss to follow-up 0 1
CD4 at baseline* 506 (31-1051) n=28 492 (199-1168) n=32 p=0,578
CD4 at end therapy 821 (385-1408) n=32
rise in CD4 after therapy
CD4 1 year after stop therapy or infection** 490 (44-882) n=22 666 (270-1310) n=29 p=0,087
CD4 2 years after stop therapy or infection 488 (245-868) n=19 569 (256-1110) n=20 p=0,500
CD4 3 years after stop therapy or infection 505 (213-1440) n=13 708 (324-1040) n=10 p=0,011
VL at baseline* 4,31 (2,04-5,00) n=28 4,87 (4,00-5,00) n=32 p<0,001
VL 1 year after stop therapy or infection** 4,42 (2,33-5) n=25 3,95 (1,70-5,00) n=29 p=0,060
VL 2 years after stop therapy or infection 4,30 (2,04-5,00) n=18 3,86 (1,70-5,00) n=20 p=0,108
VL 3 years after stop therapy or infection 4,05 (1,80-5,00) n=13 3,63 (1,70-4,80) n=10 p=0,172
mean values (min-max)
* different time point after infection for treated and 
untreated individuals
** CD4 and VL values were taken from the period 
between 8 and 12 months of follow-up
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Drug-Resistant Variants That Evolve During Nonsuppressive
Therapy Persist in HIV-1–Infected Peripheral Blood
Mononuclear Cells After Long-Term Highly Active
Antiretroviral Therapy
Chris Verhofstede, PhD,* Ann Noe¨, MD,* Els Demecheleer, BSc,* Nancy De Cabooter, BSc*
Filip Van Wanzeele, MD,† Bea Van Der Gucht, MD,† Dirk Vogelaers, MD,† and Jean Plum, MD*
Abstract: The aim of this study was to determine whether drug-
resistant virus persists in peripheral blood mononuclear cells
(PBMCs) after long-term suppression of virus replication. Proviral
DNA was extracted from the PBMCs of 11 patients on long-term
highly active antiretroviral therapy (HAART). Genotyping of the re-
verse transcriptase (RT) and protease gene of several proviral variants
was performed using limiting dilution polymerase chain reaction and
single-copy sequencing. All patients were on successful HAART for
a mean period of 59 months but had a history of suboptimal therapy
and genotypic drug resistance before. Comparison of the amino acid
sequence of the RT and protease gene in the different proviral vari-
ants, with that of the plasma virus isolated before HAART treatment,
revealed that the different drug-resistant viral variants that evolved
during the process of gradually building up resistance were still de-
tectable in the PBMCs in 10 of the 11 patients tested. The proportion
of resistant variants was found to correlate with the time that the re-
sistant variants had been able to replicate. These data clearly show
that virus variants that are able to replicate for a certain period enter
the latent reservoir and remain archived in the PBMCs for a very long
period.
Key Words: drug resistance, provirus, latent reservoir, persistence of
drug resistance
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INTRODUCTION
Despite a decrease in plasma viral RNA to below the
level of detection after starting highly active antiretroviral
therapy (HAART), virus persists for a very long period in what
is called the latent reservoir.1–6 Our current knowledge of this
reservoir (i.e., how it originates, how it is maintained and even-
tually renewed) is still very limited. An important stable long-
term viral reservoir in patients on HAART is thought to be
composed of resting memory CD4+ T cells carrying replica-
tion-competent viral genomes.1,2 The proportion of these cells
is supposed to be low, but as demonstrated recently, they per-
sist for many years even in the absence of active virus replica-
tion.7 Finzi et al.3,4 showed that a latently infected CD4+ T-cell
compartment becomes established very early in infection, but
the factors that are involved in the maintenance and eventual
replenishment of this compartment are still largely unknown.
Moreover, much debate continues about the importance of re-
sidual viral replication as a mechanism of replenishment of the
latent reservoir during HAART.4,8–10
If not fully suppressive, any antiretroviral treatment used
today will result in the development of resistance. We and oth-
ers have shown that in the majority of patients with drug-
resistant virus, treatment interruption results in the reemer-
gence of drug-susceptible HIV-1.11–13 These observations
have evoked large interest in structured treatment interruptions
as a way to reduce the amount of resistant virus to very low
levels, thereby possibly increasing the chance of durable viral
suppression on subsequently resumed therapy.13–16 The re-
sults of these structured treatment interruption studies are still
controversial but a fast reemergence of resistant variants under
the selective pressure of the new antiretroviral regimen has
been demonstrated already.17,18 If and to what extent resistant
virus enters the latent reservoir, and for how long it persists in
this reservoir, are still unknown. A better insight into the ki-
netics of the latent virus reservoir and its composition with
regard to wild-type and resistant virus might help to improve
the strategies for successful treatment of heavily exposed in-
dividuals.
To study the persistence of proviral sequences carrying
drug-resistant mutations, we selected 11 patients who were on
fully suppressive HAART for several years but who had been
exposed to suboptimal therapy previously. The main objective
was to see whether many years of selection for drug-resistant
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virus followed by a long period of suppression of replication
would lead to the disappearance of the wild-type drug-
sensitive virus and replacement by mutant drug-resistant virus
in the reservoir. Also, we wanted to examine the value of
sequencing of the cellular provirus as a way to obtain infor-
mation about previous drug resistance. We used limiting
dilution polymerase chain reaction (PCR) followed by se-
quencing of the single-copy PCR products to genotype the re-




Eleven patients were selected from the patient cohort of
the AIDS Reference Center of the University Hospital in
Ghent, Belgium. Patients from this cohort are followed inten-
sively. Enrollment was based on the following criteria: the pa-
tients had received suboptimal treatment before HAART, they
carried drug-resistant virus as revealed by sequencing at the
time of HAART initiation, and they had currently been on
HAART for >4 years. Viral load determinations during
HAART were performed at least every 2–3 months. Viral load
remained undetectable (<50 copies/mL) during the whole pe-
riod with exception of 1 occasional positive result (206
copies/mL) after 48 months of HAART in patient 1. Viral load
returned to <50 copies/mL in a sample taken from this patient
1 month later. Before HAART, the patients were treated with
either zidovudine (AZT), zalcitabine (ddC), didanosine (ddI),
or lamivudine (3TC) as monotherapy or in combination. One
patient participated in a nonnucleoside reverse transcriptase
inhibitor (NNRTI) trial and received the drug loviride. Subop-
timal therapy was given for a mean period of 46 months. Most
patients received a total of 2 or 3 drugs. During the pre-
HAART treatment, plasma was collected every 3–6 months
for viral load determination. In all patients, the viral load
remained detectable during the whole pre-HAART treatment
period.
At the time the peripheral blood mononuclear cell
(PBMC) samples were taken, all patients were on HAART for
a mean period of 59 months (range 54–68) with a combination
of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1
or 2 protease inhibitors (PIs). All patients were white and in-
fected with subtype B virus. Their mean age was 43 years
(range 32–54).
HIV RNA Quantification
Plasma samples were obtained at each visit and stored at
−70°C. HIV RNA quantification was performed using the Ul-
trasensitive Cobas Amplicor HIV-1 Monitor Test (Roche Mo-
lecular Systems, Branchburg, NJ) with a detection limit of 50
copies/mL.
DNA Extraction and Limiting Dilution PCR
DNA was extracted from freshly isolated PBMCs using
the QIAamp Blood Kit (QIAGEN GmbH, Hilden, Germany).
DNA samples were diluted 10-fold and 5 µL of this dilution
was added to each of at least 40 identical PCR mixes contain-
ing the outer primer set (sense 5-ATGATGCAGAGAG-
GCAATTT-3; antisense 5-TTCTGTATGTCATTGA-
CAGTCCAGC-3) to amplify an approximately 1200-bp frag-
ment spanning the protease and the first 240 amino acids of the
RT gene. Amplification was performed for a total of 35 cycles
(20 seconds at 94°C, 20 seconds at 50°C, and 1 minute at
72°C), after which 2 µL of the amplified products were trans-
ferred to 48 µL of 2 reaction mixes containing either a primer
set to amplify the protease gene (sense 5-AGAGCCAACAG-
CCCCACCA-3; antisense 5-GGGCCATCCATTCCTG-
GCTT-3) or a primer set to amplify the first part of the RT
gene (sense 5- CCAAAAGTTAAACAATGGCCATTGAC-
AGA-3; antisense 5-AGTTCATAACCCATCCAAAG-3).
Nested PCR amplification was performed for 30 cycles (20
seconds at 94°C, 20 seconds at 57°C, and 30 seconds at 72°C).
Positive PCR products were selected for sequence analysis
only if less than one-third of the replicate reactions were found
positive. DNA samples for which more than one-third of the
reactions were positive were diluted 10-fold further, and the
PCR reactions were repeated until a dilution was found for
which no more than one-third of the reactions were positive.
Both positive and negative controls were included in all PCR
assays to assess the sensitivity of the reaction and to detect
possible contamination. The lower limit of detection of the
PCR assay was equivalent to 1 copy per reaction. All positive
PCR products were sequenced.
Sequencing
Direct sequencing of both sense and antisense strands of
the inner PCR products was done with the dRhodamine Ter-
minator Cycle Sequencing Ready Reaction kit (Applied Bio-
systems, Foster City, CA). The sequencing reaction was per-
formed with the same primers as the ones used in the inner
PCR reactions, but to obtain a full sequence of both strands of
the RT gene fragment, 2 additional sequencing reactions were
run with internal primers (sense 5- GGGNGAYGCA-
TATTTTTCARTWCC-3; antisense 5- CCTGGTGTYTCA-
TTRTTTRYACTT-3). Sequencing reaction products were
analyzed on an ABI 310 Genetic Analyzer (Applied Biosys-
tems). A minimum of 11 (range 11–18) different PCR products
were sequenced for each patient sample. The principle of lim-
iting dilution sequencing is based on the mathematical calcu-
lation that if no more than one-third of replicate PCR reactions
are positive, the likelihood that the PCR products are the result
of the amplification of only 1 molecule is ∼70%. Limiting di-
lution sequencing allows us to obtain an accurate profile of the
distribution of different variants in a single sample.19
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The likelihood of comparing single provirus sequencing data is
further enhanced by withdrawing all sequencing products for
whom visual inspection of the electropherograms revealed
nucleotide mixtures at 1 positions. Sequences containing
stop codons or frame shifts indicating defective virus were also
withdrawn. Sequencing results were only used in the analysis if
the sequence of both strands was available and fully concordant.
Genotypic Analysis of Plasma Viral RNA
RT-PCR of the RT and protease genes was performed on
stored plasma viral RNA using the Titan One Tube RT-PCR
System (Roche Molecular Systems). Direct sequencing of the
PCR product was done as described for the proviral DNA
samples. Amino acid substitutions were identified by compari-
son of the plasma RNA sequences with a consensus HIV-1
subtype B sequence.
Phylogenetic Analysis
Nucleotide sequences were assembled using the BioEdit
package (www.mbio.ncsu.edu/BioEdit). Phylogenetic analy-
ses and neighbor-joining tree reconstructions were performed
using programs from version 3.6 of the PHYLIP package
(http://evolution.genetics.Washington.edu/phylip), with a
maximum likelihood distance matrix and a transition to trans-
version ratio of 2.0. Approximate confidence limits for indi-
vidual branches were assigned by bootstrap resampling with
1000 replicates. Tree diagrams were plotted with Treeview
v1.4 (http://taxonomy.zoology.gla.ac.uk/rod/treeview).
Nucleotide Sequence Accession Numbers
The nucleotide sequences reported in this paper have




Table 1 summarizes the treatment history and response
to HAART for the patients enrolled in the study. Patients are
ordered according to the time on suboptimal therapy. All pa-
tients showed a rapid decline in plasma viral load to below the
levels of quantification (<50 copies/mL) after initiation of
HAART. Values all remained undetectable on repeated mea-
surements during the whole treatment period. HAART also re-
sulted in an important increase in CD4 count (mean CD4 rise:
575, range 203–837).
Proviral DNA Sequencing
Table 2 summarizes the results of the sequencing analy-
sis of the RT gene of proviral DNA variants isolated from
PBMCs collected after an average HAART period of 59
months and the results of the sequencing analysis of the RT
gene of plasma virus isolated from consecutive blood samples
during the pre-HAART period. Baseline plasma samples were
not always available (missing for patients 6, 8, 9, 10, and 11).
The proviral DNA was shown to be constituted of a mixture of
wild-type proviruses and drug-resistant proviruses in 9 of the
11 patients studied. Only in patient 1 were no drug-resistant
proviral variants detected. This patient had been on suboptimal
therapy for the shortest period (11 months). In patient 9, only
variants with resistant mutations were found. This patient had
been on suboptimal therapy for a long period (5 years), indi-
cating a possible association between the time on suboptimal
therapy and the amount of resistant proviral variants. This as-
sumption is further strengthened by the observed overall cor-
relation between the time on suboptimal therapy and the rela-





















1 32 AZT 11 d4T + 3TC + RTV + SQV 60 4.41 <1.70 297 781
2 47 AZT-ddC-ddl 15 d4T + 3TC + RTV + SQV 68 4.39 <1.70 <100 781
3 49 AZT-ddC-ddl-3TC 20 AZT + 3TC + RTV + SQV 59 4.59 <1.70 144 455
4 54 AZT-3TC 22 d4T + RTV + SQV 62 5.12 <1.70 324 979
5 34 AZT-ddC-ddl 27 d4T + 3TC + RTV + SQV 60 4.89 <1.70 121 737
6 41 AZT-ddC-LV 48 d4T + ddl + RTV + SQV 54 4.64 <1.70 347 735
7 43 AZT-ddl 50 d4T + 3TC + RTV + SQV 55 4.82 <1.70 168 1005
8 45 AZT-ddC 60 d4T + 3TC + IDV 60 4.31 <1.70 305 1034
9 47 AZT-ddl 60 d4T + ddl + RTV + SQV 60 4.32 <1.70 388 591
10 41 AZT-ddC 67 d4T + 3TC + NFV 57 4.08 <1.70 249 871
11 41 AZT-ddC 96 d4T + 3TC + RTV + SQV 55 4.03 <1.70 594 1388
AZT, zidovudine; ddC, zalcitabine; ddl, didanosine; LV, loviride; 3TC, lamivudine; d4T, stavudine; RTV, ritonavir; SQV, saquinavir; IDV, indinavir; NFV, nelfinavir.
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TABLE 2. Results of the Sequence Analysis of the RT Gene in Viral RNA Isolated From Consecutive Plasma Samples Taken























1 01-18-96 no — — — — — — — — — d4T + 3TC + RTV + SQV
03-11-96 AZT — — — — — — — — —
04-05-96 AZT — — — — — — — — —
05-31-96 AZT — N — R — — — — —
07-26-96 AZT — N — R — — — Y —
09-23-96 AZT — N — R — — — Y —
12-12-96 AZT — N — R — — — Y —
12-13-96 Start HAART
2 04-19-95 no — — — — — — — — — d4T + 3TC + RTV + SQV
06-19-95 AZT — — — — — — — — —
08-01-95 AZT + ddC — — — — — — — Y —
09-21-95 AZT + ddC — N — R — — — Y —
11-09-95 AZT + ddC — N — R — — — Y —
12-12-95 ddI — — — — — — — — —
02-14-96 ddI — N — R — — L/W Y K/E
04-09-96 ddI — N — R — — L/W Y K/E
08-01-96 ddI — N — K/R — — — Y E
09-03-96 Start HAART
3 05-23-95 no AZT + 3TC + RTV + SQV
06-13-95 AZT — — — — — — — — —
08-01-95 AZT + ddC — — — — — — — — —
09-25-95 AZT + ddC — — — — — — — Y —
12-14-95 AZT + ddC — N — R — — — Y —
01-15-96 AZT + ddC — N — R — — — Y —
06-06-96 AZT + ddI — — — — — — — Y —
07-25-96 AZT + ddI — — — — — — — Y —
08-21-96 AZT + ddI L — — — — — W Y —
10-18-96 AZT + 3TC L — — — — V W Y —
01-27-97 Start HAART
4 05-09-95 no — — — — — — — — — d4T + RTV + SQV
06-15-95 AZT + 3TC — — — — — M/V — — —
07-13-95 AZT + 3TC — — — — — V — — —
10-11-95 AZT + 3TC — — — — — V — — —
12-13-95 AZT + 3TC — D/N — K/R — V — — —
03-20-96 AZT + 3TC — N — R — V — — —
05-15-96 AZT + 3TC — N — R — V — — —
09-18-96 AZT + 3TC — N — R — V — I Q
11-19-96 AZY + 3TC — N — R — V — I/F Q
03-27-97 Start HAART — N — R — V — F Q
5 10-28-94 no — — — — — — — — — d4T + 3TC + RTV + SQV
03-23-95 AZT + ddC — — — — — — — — —
05-15-95 AZT + ddC — — — — — — — — —
08-16-95 AZT + ddC — N — R — — — Y —
02-26-96 AZT + ddI — — — K/R — — — Y/F —
07-17-96 AZT + ddI — D/N — R — — L/W Y/F E
12-16-96 AZT + ddI — N — R — — W Y/F E
03-24-97 AZT + ddI L N — R — — W Y E
04-07-97 Start HAART L N — R — — W Y E
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TABLE 2. (continued) Results of the Sequence Analysis of the RT Gene in Viral RNA Isolated From Consecutive Plasma Samples
Taken During the Pre-HAART Period (Left) and in Proviral DNA Isolated From a Single PBMC Sample Taken After Several Years























1 13-03-01 18 — — — — — — — — —
2 05-23-02 5 — — — — — — — — —
1 — — — — — — — Y —
4 — N — R — — — Y E
1 — N — R — — W Y E
3 12-03-01 14 — — — — — — — — —
1 — — — — — — — Y —
1 — N — R — — — Y —
1 L — — — — V W Y —
4 05-15-02 10 — — — — — — — — —
1 — N — R — V — — —
1 — N — R — V — F Q
5 04-08-02 8 — — — — — — — — —
1 — — — — — I — — —
1 — N — R — — — — —
3 — N — R — — — F E
2 — N — R — — W Y E
1 L N — R — — W Y E
1 L N N R — — W Y E
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TABLE 2. (continued) Results of the Sequence Analysis of the RT Gene in Viral RNA Isolated From Consecutive Plasma Samples
Taken During the Pre-HAART Period (Left) and in Proviral DNA Isolated From a Single PBMC Sample Taken After Several Years






















6 02-28-94 AZT L — — — — — L/W Y — d4T + ddI + RTV + SQV
05-24-94 AZT + ddC + LV L — — — — — L/W Y —
06-29-94 AZT + ddC + LV L — — — — — W Y —
08-05-94 AZT + ddC + LV L — — — — — W Y —
01-23-95 AZT + ddC + LV L — — — — — W Y —
05-23-95 AZT + ddC + LV L — — — N/K — W Y —
05-30-96 AZT + ddC + LV L — — — N — W Y —
08-23-96 Start HAART
7 02-03-93 no — — — — — — — — —
01-12-94 AZT M/L — — — — — — T/Y —
06-15-94 AZT — — — — — — — T/Y —
08-17-94 AZT M/L — — — — — — Y —
03-15-95 AZT L — — — — — L/W Y —
03-13-96 AZT + ddI L — — — — — W Y —
07-04-96 AZT + ddI L — — — — — W Y —
11-20-96 AZT + ddI L — — — — — W Y —
04-09-97 Start HAART L E — — — — W Y —
8 03-17-94 AZT — — — R — — — — — d4T + 3TC + IDV
03-08-95 AZT — — — R — — — Y —
04-26-95 AZT — D/N — R — — — Y/T Q/K
05-16-95 AZT + ddC — D/N — R — — — Y/T —
10-16-95 AZT + ddC — N — R — — — Y Q
03-26-96 AZT + ddC — N — R — — — Y Q
06-24-96 AZT — N — R — — — Y/T —
09-03-96 AZT — N — R — — — Y Q
01-17-97 Start HAART
9 09-11-95 AZT — D/E — R — — — — Q/K d4T + 3TC + RTV + SQV
11-13-95 AZT — E — R — — — — —
01-10-96 AZT + ddI — D/N — R — — — T/F Q
09-30-96 AZT + ddI — N — R — — — F Q
03-24-97 Start HAART — N — R —- — — F Q
10 03-11-93 AZT — — — — — — — — — d4T + 3TC + NFV
01-05-95 AZT — — — — — — — — —
01-09-96 AZT — — — R — — — — —
02-06-96 AZT — — — R — — — I —
05-06-96 AZT — — S/T K/R — — — T/Y —
10-07-96 AZT — — — R — — — — —
11-12-96 AZT + ddC — — — — — — — Y —
01-13-97 AZT + ddC — — — — — — — Y —
04-01-97 Start HAART — — — — — — — Y —
11 11-23-92 AZT — — N R — — — — — d4T + 3TC + RTV + SQV
04-21-93 AZT — — N R — — — — —
09-22-93 AZT — — N R — — — — —
03-01-94 AZT — — N R — — — — —
07-25-94 AZT + ddC — — N R — — — — —
04-10-95 AZT + ddC — — N R — — — — —
08-07-95 AZT + ddC — G/D N R — — — — —
11-13-95 AZT + ddC — G N R — — — — Q
03-12-96 AZT + ddC — G N R — — — — Q
04-07-97 Start HAART — G N R — — — — Q
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TABLE 2. (continued) Results of the Sequence Analysis of the RT Gene in Viral RNA Isolated From Consecutive Plasma Samples
Taken During the Pre-HAART Period (Left) and in Proviral DNA Isolated From a Single PBMC Sample Taken After Several Years























6 02-05-01 2 — — — — — — — — —
2 L — — — — — — Y —
3 L — — — — — W Y —
2 L — — — N — W — —
3 L — — — N — W Y —
7 11-21-01 2 — — — — — — — — —
2 L — — — — — — Y —
2 L — — — — — W Y —
7 L E — — — — W Y —
8 03-12-02 4 — — — — — — — — —
4 — N — R — — — — —
4 — — — R — — — Y —
1 — N — R — — — Y —
1 — N — R — — — Y Q
9 03-06-02 3 — — — R — — — — —
1 — E — R — — — —
1 — N — R — — — — —
1 — N — R — — — — Q
1 — G — R — — — F Q
8 — N — R — — — F Q
1 L N — R — — — F Q
10 01-07-02 4 — — — — — — — — —
7 — — — R — — — — —
4 — — S R — — — — —
11 11-21-01 2 — — — — — — — —
3 — — — R — — — — —
7 — — N R — — — — —
2 — G N R — — — — —
4 — G N R — — — — Q
*Number of proviral variants with the corresponding mutational pattern.
AZT, zidovudine; ddC, zalcitabine; ddl, didanosine; 3TC, lamivudine; d4T, stavudine; LV, loviride; RTV, ritonavir; SQV, saquinavir; IDV, indinavir; NFV,
nelfinavir.
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tive amount of mutant sequences between the proviral variants
(logistic regression coefficient r2 = 0.6308; P = 0.004)
(Fig. 1).
The number of different proviral variants that were de-
tected in 1 sample varied from 3 to 8. Proviral variants with
resistant mutations were heterogeneous in all patients; variants
with either different numbers of mutations or different combi-
nations of mutations were detected in the same patient. Results
of sequencing analysis performed retrospectively on stored
plasma samples revealed that most of these variants had been
circulating in the plasma transiently during the period of sub-
optimal therapy (Table 2). Proviral variants with additional
mutations as compared with the variants found in plasma were
seen in only 1 patient (patient 5). This patient carried a variant
with an additional M184I mutation and a variant with an addi-
tional T69N mutation. Proviral variants with PI-associated pri-
mary mutations were not observed (data not shown).
Phylogenetic Analysis
After aligning the whole nucleotide sequence of about
1000 base pairs (protease gene and part of the RT gene) of all
proviral and viral variants, a phylogenetic tree was constructed
for each patient. The codons associated with resistance were
removed from the alignment before the phylogenetic analysis
was performed so that the tree topology was not determined by
the resistance mutations. All trees showed a pronounced inter-
mingling of viral and proviral sequences. No indications for a
separate evolution within the provirus population were found.
Despite removal of codons associated with resistance muta-
tions before the analysis, variants with the same resistance pat-
tern always clustered together. Two representative trees are
shown in Figure 2. One tree is constructed from the results of
patient 3. This patient had been on suboptimal therapy for 20
months. The proportion of wild-type variants in the provirus is
high. Drug-resistant viral and proviral variants cluster together
but bootstrap support for clustering was low (<50%). The sec-
ond tree is constructed from the results of patient 7. This pa-
tient had been on suboptimal therapy for 50 months. The pro-
portion of wild-type variants in the provirus is low. An inter-
mingling of viral and proviral variants can be observed, and
there is no evidence for a separate evolution of the provirus
population.
DISCUSSION
Although advances in HIV treatment have reduced the
morbidity and mortality rates among HIV-infected individu-
als, all currently prescribed antiretroviral drugs fail to elimi-
nate the latent reservoir and it is clear that, with the current
treatment strategies, eradication of the virus will never be pos-
sible. Therapy has to be taken for life, and this is complicated
due to the adverse effects of the drugs and due to the emer-
gence of drug resistance. HIV-infected individuals in whom
drug regimens have repeatedly failed often harbor virus with
multiple drug resistance–associated mutations. Although it has
been shown that stopping therapy or switching from one class
of drugs to another leads to the disappearance of the resistant
strains from the plasma in the majority of cases, the question of
whether this also will enable recycling of these drugs in the
future is not yet clearly answered.11,12 Although viral latency
under HAART is the subject of several studies, the mecha-
nisms of HIV persistence and reservoir establishment remain
largely unknown.2–5,7,8,20,21
We studied the variability of the RT and protease gene in
the provirus of patients who were under long-term HAART but
who had a history of suboptimal therapy in the past. Our results
confirm the observations of others that cells containing HIV-1
provirus remain detectable for periods extending several
years.7,10 Proviral sequences with a fully wild-type RT gene
were found in 10 of the 11 patients despite the fact that in all
these patients drug-resistant mutants have been favored by the
selective conditions for many years. For the 1 patient in whom
no wild-type proviral variants were detected, no pretreatment
plasma samples were available so we cannot exclude the pres-
ence of the 70R mutation as a polymorphism already before
starting medication.
In accordance with the findings in HIV-1–infected chil-
dren, our results show that viruses in the latent reservoir are
diverse and reflect selection by the pre-HAART regimens.21
From the results of this study we have arguments to support the
observation also made recently by Strain et al.10 that the main-
tenance of the cellular reservoir is a dynamic process. New
variants that are able to replicate for a certain period enter the
FIGURE 1. Association between the time on suboptimal
therapy and the proportion of proviral sequences with drug
resistance–associated mutations in the RT gene. The propor-
tion of proviral sequences with drug resistance–associated mu-
tations is expressed as percentage of the total number of ana-
lyzed proviral sequences for that patient. Logistic regression
coefficient r2 = 0.6308; P = 0.004.
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reservoir to be conserved for longer periods. With a few ex-
ceptions, all mutant virus variants that were found in the
plasma during the process of gradually building up resistance
were still detectable several years later in the provirus. From
the correlation that we observed between the period on subop-
timal therapy before HAART and the proportion of mutant
proviral sequences in the PBMCs, we can conclude that the
quantity that a certain variant occupies within the reservoir will
depend in part on the period that this variant has been able to
replicate. However, the slow fading out of the oldest vari-
ants—in these cases the wild-type variants—might also con-
tribute to the observed correlation.
We were not able to find indications for a further virus
evolution under HAART. Only in patient 5, two observations
might reflect some evolution: the detection of a 184I-carrying
proviral variant and a 69N variant in provirus but not in
plasma. The patient was on a combination of stavudine
(d4T) + 3TC + ritonavir (RTV) + saquinavir (SQV) and se-
lection of a 69N by this combination is possible, although
it is more likely that this mutant arose during the pre-HAART
bitherapy with AZT and ddI but was missed in plasma.
The 184I mutation is known to be a 3TC-resistant transient
intermediate stage between the wild-type 184M and the 3TC-
resistant 184V.22 Because 3TC is a component of the HAART
regimen and the patient has never taken 3TC before, the
chance is high that this variant arose during the HAART
period. However, we cannot exclude the occurrence of 184I as
a natural polymorphism. In this regard it is important to note
that the 184I mutation was detected in a proviral variant with
an otherwise completely wild-type background. 3TC was a
component of HAART in 9 of the 11 patients, but no other
patients showed proviral sequences with mutations at codon
position 184.
PIs were a component of the HAART regimen in all
patients but no additional PI-associated mutations compared
with the secondary mutations already present in the plasma
FIGURE 2. Rooted neighbor-joining trees of the HIV-1 protease
and RT gene from viral RNA (bars) and proviral DNA (squares)
of patients 3 and 7. Viral RNA was isolated from plasma at
different time points during nonsuppressive therapy (date of
sampling is indicated in the bar). Proviral DNA was isolated
from a single PBMC sample taken after 59 months (patient 3)
and 55 months (patient 7) of successful HAART. The resistance
pattern of each isolate is indicated but the codons associated
with drug resistance mutations were removed from the
nucleotide alignment before phylogenetic analysis. Trees were
rooted with a reference subtype B strain (B.FR.83.HX). The
numbers at the nodes indicate proportion of support in 1000
bootstrap resamplings. Only bootstrap proportions of 50%
are indicated. WT, wild-type, no resistance-associated muta-
tions detected.
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virus before HAART initiation were detected (results not
shown). An additional argument against further evolution
of proviral sequences is the fact that phylogenetic analysis
revealed intensive intermingling of proviral and viral variants
in all patients.
Currently, plasma is the only compartment used rou-
tinely for drug resistance testing and studies that address the
role of the cellular reservoir with regard to emerging drug re-
sistance and conservation of drug resistance are limited.21 Our
results show that infected PBMCs of patients under HAART
contain a heterogeneous mixture of different viral variants. Be-
cause of this heterogeneity, population-based sequencing of
provirus will presumably only detect major variants and will
not provide valuable information about the resistance poten-
tial. Limiting dilution sequencing, conversely, was shown to
allow detection of archived viral resistance, but the method is
time consuming and expensive and therefore not suitable for
large-scale use. It also remains to be examined to what extent
the archived viruses remain replication competent. In this
study, 10 sequences with stop codons, frame shifts, or hyper-
mutations were found on the total of 173 sequences that were
analyzed and they were removed from the analysis. However,
our observations are limited to the HIV-1 protease and part of
the RT gene and we cannot exclude the occurrence of muta-
tions resulting in defective virus elsewhere in the genome. De-
spite the fact that we have no evidence for the replication com-
petence of the archived proviral sequences, we consider the
lack of any selective pressure that might be induced by in vitro
culture as an important advantage, allowing a better estimate
of the quantitative distribution of the different proviral variants
present.
The results described here have important clinical impli-
cations because they confirm the long-term persistence of any
drug-resistant virus once it has arisen, thereby permanently
jeopardizing certain treatment options. In the patients studied
here, HAART was initiated at a time when resistance testing
was not performed. It is important to notice that, with the cur-
rent knowledge, several of the drug combinations used at that
time would no longer be prescribed in these patients, consid-
ering the observed genotypic resistance patterns. However,
even with a suspected “less active” HAART, all patients
showed a long-term virologic and immunologic response to
the treatment, indicating that drugs to which resistance is pre-
dicted can still have therapeutic value in a combination regi-
men. Besides the fact that resistance is seldom an all-or-
nothing phenomenon and low-grade resistance can be over-
come by high drug concentrations, the results of this study
point to another possible explanation for this observation, the
fact that despite the detection of fully resistant virus in plasma,
the majority of infected cells might still contain wild-type vi-
rus. As part of a combination regimen, drugs to which resis-
tance has been developed can still add to the activity of the
combination by preventing the replication of this latent wild-
type, drug-sensitive, virus pool.
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The latent HIV-1 reservoir in patients undergoing HAART:
an archive of pre-HAART drug resistance
Ann Noe¨, Jean Plum and Chris Verhofstede*
AIDS Reference Laboratory, Ghent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium
Recent studies on patients with a history of pre-HAART drug resistance, but currently on a successful
regimen, provided new insights into the dynamics of the latent cellular viral reservoir. Results indi-
cated that the latent reservoir is an archive, composed of a mixture of wild-type and drug-resistant
strains. The studies showed that, even after years of successful HAART, the wild-type viral strains that
circulated before the initiation of the therapy as well as all the different drug-resistant viral strains that
evolved over time during eventual periods of non-suppressive treatment, remain detectable in the pro-
viral reservoir. These findings support the hypothesis that during active viral replication, new variants,
including drug-resistant ones, continuously enter the latent viral reservoir. It can be concluded that, as
a consequence of the lifelong conservation of this latent reservoir, the potency of drugs for which
resistance once developed will remain reduced, even after years of withdrawal of the drug.
Keywords: reservoirs of resistance, mechanisms of resistance, mutations
Introduction
Since the availability of sensitive assays for viral load quantifi-
cation in plasma, it has become clear that HIV-1 infection is
characterized by a continuous massive virus replication, even
during the asymptomatic phase of the disease. Although the
immune system exerts some control, it generally fails to
completely arrest the replication or reduce it to a form of true
latency as is seen for other viral infections. The process of con-
tinuous virus replication can be interrupted or at least signifi-
cantly reduced by HAART. But, although the introduction of
HAART results in undetectable levels of plasma virus in the
majority of patients, HAART fails to completely eradicate the
virus in vivo, even after years of uninterrupted therapy. Viral
persistence is thought to be the result of the long-term survival
of a pool of infected, resting CD4 cells. Recent studies in
patients on successful HAART but with a history of pre-
HAART drug resistance, provided new evidence for the dynamic
nature of the latent reservoir and showed that any viral variant,
including any drug-resistant variant that has been allowed to
replicate for a certain time during the infection, will enter the
reservoir and remain conserved.
Long-term latent reservoir
Finzi et al.1 showed the establishment of a latently infected CD4
cell compartment already very early in infection. The cellular
reservoir is found predominantly in resting DR–CD4 cells with
a memory phenotype.2,3 The half-life of these cells is long (44
months) and this long lifespan, combined with the possibility of
self-renewal by proliferation, ensures their lifelong presence.
How these cells originate is still a matter of controversy, but it
has been postulated that the reservoir of latently infected cells is
generated when lymphoblasts that are in the process of reverting
to a resting state, become infected.4,5 Whether the long half-life
of the infected cells is the only reason for the persistence of
these cells during HAART treatment or whether the latent pool
is fully or partly maintained by ongoing low-level viral replica-
tion despite treatment, has long been unclear. But the lack of
detectable evolution in the envelope and polymerase sequences
of viral strains in the cellular reservoir during HAART, argues
against entry of new genotypes in the latent pool during success-
ful treatment, and supports the belief that persistence depends
primarily on the intrinsic stability of the infected cells.6
The HIV reservoir during HAART treatment
In patients on successful HAART, the presence of resting CD4
cells harbouring replication-competent virus has been demon-
strated by several groups.1,7 – 9 In line with these observations is
the consistent clinical finding of a quick rebound of plasma virus
in all patients who stop treatment, indicating the presence of a
latent reservoir that enables quick reinitiation of replication
whenever the drug pressure is removed.10,11
But perhaps the most convincing argument for long-term con-
servation of viral strains comes from the observation that a ces-
sation of treatment or a switch of antiretroviral drugs in patients
treated for more than 2 years with suboptimal drug regimens,
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resulted in the replacement of the resistant virus in the plasma
by wild-type variants.12 – 14 In the majority of the patients studied,
the replacement of the mutant by the wild-type virus was abrupt
and fast, indicating that it was the result of the reappearance of
archived wild-type virus and not of the reversal of mutations in
the resistant variants. This finding was remarkable since drug-
resistant virus predominated in the plasma of these patients for
several years and at least an important reduction in the popu-
lation of wild-type virus through a natural process of cell death
could be presumed. If wild-type virus persists in the latent
reservoir for such a long time, then it could be postulated that
drug-resistant strains too will be conserved.
Ruff et al.15 were the first to demonstrate that drug-resistant
viruses, selected by non-suppressive regimens in infected chil-
dren, entered the reservoir and persisted during HAART. Sub-
sequently, Lambotte et al.16 compared a polymorphic region of
the env gene and part of the reverse transcriptase gene in pre-
HAART plasma and in the reservoir lymphocytes, in nine treated
patients with long-term undetectable plasma viral load. They
observed archiving of pre-HAART plasma clones in six patients
and confirmed the co-existence of wild-type and drug-resistant
virus in reservoir T cells in two. We studied the variability of
the RT and protease gene in the provirus of 11 patients on suc-
cessful HAART for years, but with a period of suboptimal regi-
mens before.17 Not only could we confirm the co-existence of
wild-type and drug-resistant virus in the proviral reservoir after
5 years or more of HAART, but we were also able to show that,
with a few exceptions, all mutant virus variants that were
detected in the plasma before HAART initiation, during the pro-
cess of gradually building up resistance, were still present in the
latent reservoir. Moreover, we observed a correlation between
the time period on suboptimal therapy before HAART and the
proportion of mutant, drug-resistant, proviral sequences in the
cells, indicating that the quantity that a certain variant occupies
within the reservoir depends in part on the period that this var-
iant has been able to replicate. These data prove that the reser-
voir of latently HIV-1-infected cells is dynamic, and that newly
infected cells continuously turn into latency to enter the reser-
voir. These data also indicate the extreme long-term conserva-
tion of all variants that have ever entered the reservoir. The
latent reservoir can be considered as the life-long archive of
whatever viral strain that ever evolved and replicated.
Clinical implications of the persistence
of drug resistance
Once it has arisen, long-term persistence of any drug-resistant
virus jeopardizes, in a permanent manner, the use of drugs to
which resistance has developed. This finding again emphasizes
the importance of considering the whole treatment history of a
patient whenever a new combination therapy is initiated. Recy-
cling of any drug that was part of a non-suppressive treatment
regimen, even if the drug was taken years ago, might result in
the reactivation of archived resistant strains and must be avoided
unless there are no valid alternatives.
However, the observation that the viral reservoir contains a
heterogeneous mix of wild-type variants and mutant variants
with different degrees of drug resistance, also indicates that even
drugs to which resistance has developed may still ‘add’ to the
activity of a combination therapy by preventing the replication
of the drug-sensitive virus pool in the reservoir. Since the wild-
type virus is believed to be the fittest variant, suppressing the
replication of these wild-type strains can be important, especially
in patients with limited treatment options, and might contribute
to the reduced viral-load set-point as is observed in many treated
patients with drug-resistant viraemia.18,19 On the other hand, con-
tinuation of a failing regimen risks the further accumulation of
drug-resistance mutations and an expansion of the reservoir of
cells infected with drug-resistant variants, and is not advisable.
Whether the proportion of cells infected with drug-resistant
strains in the latent reservoir has any impact on the success or
failure of subsequent salvage regimens still remains to be
examined.
Currently, plasma is the only compartment used routinely for
drug resistance testing. However, the observation that the pro-
viral compartment contains an archive of the different strains,
wild-type and drug-resistant, that have evolved during the infec-
tion, makes this proviral reservoir the ideal substrate for analysis
of the ‘resistance-potential’ in a patient. This can be of special
importance in those patients from whom no samples have been
conserved and no historical data are available.
Conclusion
An important number of data indicate that the long-lived cellular
reservoirs of HIV in patients reflect a heterogeneous population
of replication-competent viral strains. The diversity of the
reservoir is dynamic and results from successive archiving of
circulating plasma viruses during the course of HIV infection,
including the drug-resistant variants. Archived variants are
assumed to remain life-long, thereby precluding the successful
recycling of any drug towards which resistance has arisen.
Our knowledge of the latent HIV-1 latent reservoir is rapidly
increasing. Only a thorough understanding of the development
and maintenance of the latent reservoir will allow the develop-
ment of new therapeutic strategies, aimed at a combined effect
of arresting viral replication and eliminating the latent reservoir.
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CHAPTER V: GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Although HAART dramatically slows the progression of HIV disease and decreases the 
transmission rate, the HIV/AIDS prevalence is still rising worldwide. This rise can be explained 
by the fact that currently (in 2005) only 17% of the patients in need of HAART are effectively 
treated (http://www.unaids.org/epi/2005/doc/report_pdf.asp).  
For the worldwide implementation of HAART the economical and logistic needs are enormous. 
At this moment, hope for a future stabilisation of the HIV/AIDS pandemic is based on these ARV 
programs which form an essential support for prevention strategies1. We must encourage 
implementation of ARV as it has been proven valuable in resource poor settings, despite the 
multiple challenges2. The WHO developed treatment guidelines, adapted to resource limited 
settings in order to treat large numbers of patients despite restricted logistic means 
(http//www.who.int/3by5/publications/documents /arv_guidelines/en/). Currently, an 
exponentially rising number of patients is treated with affordable drug regimens through several 
ARV implementation projects. However, fear exists that the improved access to treatment will 
result in the emergence and spread of resistant viruses. Efforts to prevent resistance are especially 
focused on counselling as good compliance is the best way to prevent its occurrence. CD4 T cell 
count and especially viral load determination help to evaluate the efficacy of an antiretroviral 
regimen and they allow the early recognition of therapy failure. Early detection of resistance 
enables a fast intervention, thereby reducing the risk of accumulated resistance mutations, of 
cross resistance and of multi drug resistance. Assays for CD4 determination and certainly for 
viral load quantification are still unaffordable in most developing countries. Cheap tests and 
strategies are urgently needed for follow-up3. Fear for resistance may not jeopardize the efforts to 
fight the virus in these resource poor settings, as yet no evidence exists that the risk for resistance 
is higher in these regions compared to the Western world 4.  
 
As access to and use of ART are improving, it is critical to define regimens which offer the 
highest benefit with a minimum of adverse effects. One approach might be to search for a 
specific treatment strategy that enables the induction of a status of long term non progression 
(LTNP). In LTNP a high number of functional HIV-specific CD4 T cells can consistently be 
found 5. A comparable conservation of the CD4 T cell responses has been reported in some 
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patients treated early in HIV-infection 6-11. In addition, a lower proviral load is observed in LTNP 
and in patients treated during acute HIV-infection, compared to patients treated during chronic 
HIV-infection. 12 Part of this thesis aimed to investigate the effect of early but temporary ART on 
HIV-infection. The effect of treatment on HIV-specific CD4 T cells and proviral load in acute 
HIV infection has in most studies been analysed while patients are still on medication. As ARV 
treatment has considerable short and long term side effects, it is of interest to examine the benefit 
of a short treatment period. Are HIV-specific CD4 T cells preserved after the treatment 
interruption? What is the evolution of proviral load after treatment interruption? Can HIV disease 
progression be delayed with a temporary treatment? What is the impact of side effects?  
 
We investigated the impact of temporary ART in acute HIV-infection on the two most generally 
used markers of disease progression: the number of CD4 T cells and the VL. We also studied the 
effect of the treatment on the immune function and we paid attention to the frequency of serious 
side effects of the medication. On the recent CROI (February 8, 2006, Early, uninterrupted 
treatment for HIV infection reduces complications, E. Susman) a study was presented in which 
over 2300 patients were evaluated for the occurrence of drug related side effects. According to 
these investigators, treatment in early infection was related with 60% less side effects compared 
to treatment in chronic infection. Also in terms of immune recovery early treatment was 
beneficial. However, they advise to continue the antiretroviral treatment without interruption. The 
better tolerance to therapy in early infection is in line with the observation of a low occurrence of 
side effects, in our patient group;  only one patient in 40 had to stop the treatment because of side 
effects.   
 
When we compared the VL and CD4 T cell count between untreated and treated patients at a 
same period of time after infection and treatment interruption respectively, we observed lower 
mean plasma VL and higher mean CD4 lymphocyte counts in the treated patients (X). This 
indicates that early temporary treatment might delay disease progression for a time period that 
exceeds the course of treatment. Because of a limited follow-up period in the untreated patients, 



















In one of the treated patients, no viral presence could be found after stopping the antiretroviral 
therapy even for a follow-up period, up to this moment, of 18 months. Obtaining a better insight 
in the underlying mechanisms that explain this efficient virus control could be very interesting. In 
this patient, viral characteristics, proviral load, HIV-specific immunity, and other host factors are 
further being studied.  
 
Whether the preserved HIV-specific immunity contributes to the better outcome is not 
unequivocally proven. In agreement with the results presented in different other studies 6-11, we 
found that ART in early infection sometimes preserves HIV-specific immunity. However, we did 
not find a correlation between the amount and diversity of HIV-specific CD8 T cell reactivity and 
plasma VL. But, our results are in favour of a possible correlation between high HIV-specific 
CD4 T cell response and suppressed plasma VL. All the individuals studied for HIV-specific 
immunity, who suppressed for a long time their viral replication, had high amounts of HIV-
specific CD4 T cells. The same numbers of immune cells, however, were also found in patients, 
who were able to only temporary suppress their viral levels. So the question remains if the HIV-
specific CD4 T cells are suppressing viral replication or if VL determines the fate of the HIV-
specific CD4 T cells.  
 
High HIV-specific CD8 T cell responses were not seen at baseline in the 5 patients that were 
tested before treatment initiation. This can be due to the fact that we addressed this parameter in 
the first 6 months after infection, before the immune response was fully developed. However, it is 
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also possible that the role of CD8 T cells might have been overestimated in the literature, as their 
response is too late and too weak 13. Also of importance is the fact that we only studied 
circulating blood cells, while most HIV-specific CD8 T cells are attracted to the lymph nodes, 
where they exert their antiviral function 14. Another possibility is that due to the baseline 
activation status of the CD8 T cells, those cells are unable to produce extra IFN-γ  in response to 
an in vitro stimulation. 
We analysed the number of HIV-specific CD8 and CD4 T cells by peptide stimulation and 
measuring intracellular IFN-γ expression. Because of the restricted number of cells available, we 
were not able to address the relation between VL suppression and IL-2 secretion or proliferation 
capacity.  
 
We also analysed the genetic background of our tested patients. An association between certain  
HLA antigens and a better outcome of the patient has been described. The genetic background is 
of importance as it is linked to the strength of the immune responses. Some HLA Class I antigens 
(HLA B27, B 63, B57, B58) are related with a better clinical outcome15-17, while HLA B35 is 
related with a faster progression of the disease18. In our cohort of acute infected patients we were 
not able to find any relation between HLA class I antigens and the immune responses or the 
disease outcome.  
 
In literature, two studies evaluating the effect of ‘Structured Treatment Interruption’ (STI) in 
early infection, have shown a limited long-term benefit after stopping the treatment 19, 20. These 
STI may not have the same impact on viral spread and proviral HIV reservoir compared to 
continuous HAART, because of the repetitive viral rebound and viral spread associated with each 
therapy interruption. The strategy of STI also includes the risk of drug-resistance 21 and of an 
enhanced loss of CD4 T cells 22.  
 
The proviral load might be a good prognostic marker to predict viral rebound after treatment 
interruption 23. Therefore several strategies have been developed aiming to reduce  the amount of 
latent HIV-infected cells. Starting HAART early after HIV-infection limits HIV proviral 
spread24. The decay rate of proviral load is observed to be higher in treated acute compared to 
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treated chronic infection. Moreover, HAART in early HIV-infection has been shown to decrease 
cell associated infectivity (CAI) 24 and gives hope to seriously limit viral rebound.  
 
Lafeuillade showed that a longer treatment period early in infection resulted in lower proviral 
load 25. In our study we also found a correlation between better outcome and a longer period of 
treatment. Studies evaluating the influence of the length of the treatment period in PHI on the 
final outcome are not done yet26. In the different studies that we found in literature, the treatment 
period varies between some weeks 11 and several years (3 years 27).  
Criteria to analyse the ideal time to stop HAART in acute HIV-infection should be defined. The 
usefulness of the total CD4 T cell number or the number of HIV-specific CD4 T cells or the 
proviral load as prognostic markers for predicting viral rebound and/or clinical outcome after 
treatment interruption must be evaluated32. Besides, larger studies with longer follow-up are 
needed to analyse the possible relation between those factors and long time control of virus 
replication after treatment stop 
 
Studies have shown that immune activation therapies, with T cell activators and/or IL-2 fail to 
eradicate HIV infection 28. On the contrary, those therapies induce an increase in T cell turnover 
and susceptible target cells thereby augmenting the viral replication. Recently, encouraging 
results are obtained with more selective strategies, which aim at activating the quiescent proviral 
genome without influencing the activation status of the immune cells by using prostratin and 
valproic acid 29-31. A possible interesting strategy to deplete HIV provirus from resting cells could 
consist of a combination of early antiretroviral treatment and prostratin and valproic acid.  
 
As only a small percentage of HIV-infected patients are diagnosed during acute HIV-infection, it 
can be argued that the studied strategy might have a limited impact on the overall HIV-infected 
population. However, in our hospital 9,7% of all the HIV-infected patients that were followed 
over the period of inclusion, were seen within the first six months of infection. Also, if a 
combination of different strategies would have a proven beneficial effect, more efforts could be 
put in programs for the active tracing of early infection. Detection of acute HIV-infection, 
through pooling of sera, has been shown feasible and cost effective 33, 34. In high risk populations, 
a significant number of patients with acute HIV-infection can be detected 35. Pilcher et al. studied 
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the prevalence of acute HIV-infection in a population consulting a clinic for sexually transmitted 
diseases (STD) in Malawi. They found a prevalence of acute HIV-infection of 5% among 
antibody-negative individuals 35. Detection of acute HIV-infection is not only important for the 
possible benefit related with ARV treatment, but also for prevention of HIV-transmission which 
is extremely high during acute HIV-infection 36-42. In addition, study of acute HIV-infection can 
help us to better understand factors related with protection and with a lower VL set point, which 
is of importance in future vaccine development and drug design.  
 
A rising problem related to the improved availability of HAART is the management of side 
effects. In the western world, a high percentage of the hospitalisations in HIV-infected 
individuals are due to side effects. Next to those side effects, also IRIS is directly linked with 
therapy intake. Fear exists that the incidence of IRIS, will seriously rise in the developing 
countries as access to treatment is improving. This relies especially on the high prevalence of 
pathogens associated with IRIS in the developing countries (Mycobacterium tuberculosis, 
Mycobacterium avium, Cryptococcus neoformans, CMV, hepatitis B and C). TB, the second 
infectious killer worldwide after HIV, is in developing countries often seen in co-infection with 
HIV. Both infections, separately and combined, are associated with IRIS after treatment 
instauration. Mycobacteria are the pathogens most frequently implicated in IRIS after 
instauration of HAART, causing approximately 40% of the IRIS cases, reported up to 2002 43. 
Especially extrapulmonary TB is a strong risk factor for paradoxical reactions 44-46. The 
distinction between inflammation and active infection as the cause of deteriorating clinical 
symptoms after treatment instauration is often not clear. Breen et al. suggested that HAART 
could induce and/or aggravate clinical symptoms of active TB infection 47.  
Little is known about the incidence of IRIS in the developing world 48. The benefits of HAART 
on HIV and the incidence of TB infection are much higher than the possible risks. It is known 
that because of HAART, the incidence of tuberculosis decreased by approximately 70-90% in 
treated cohorts living in high and low income countries 49-52.  
Interaction of HIV with other highly prevalent tropical diseases can have a high impact on 
worldwide morbidity and mortality. HIV induced immune dysfunction increases the incidence of 
malaria 53 and severe malaria 54, 55 while Plasmodium falciparum parasitaemia on the other hand, 
causes higher plasma VL 56. The effect of malaria on HIV disease progression and HIV 
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transmission rate remains to be elucidated 57. No IRIS has been described related to Plasmodium 
falciparum. 
 
The incidence of IRIS can possibly be reduced by early treatment of OI’s in immune 
compromised patients and/or by early ARV treatment of HIV-infection, thereby avoiding serious 
immune dysfunction. This also requires broader use of screening methods and a better access to 
medical care to detect infections in an earlier or clinical latent stage. This is extremely difficult as 
in these immune compromised persons, expression of symptoms is often delayed, while at the 
time of detection the TB infection is more likely to be multibacillary.    
For the many HIV-infected patients consulting in an advanced stage of the HIV-infection, a better 
understanding of the mechanisms responsible for IRIS can be useful to enable an adaptation of 
treatment strategies and guidelines for TB/HIV co-infected patients. Anti-inflammatory drugs and 
glucocorticosteroids have been shown to give relieve 58, 59. Also surgery and therapeutic 
aspiration are often needed. Pires et al. observed a clinical and immunological benefit of 
concomitant administration of HAART and immune therapy with IL-2 plus GM-CSF 60. They 
suggested that IRIS is associated with an inadequate recovery of immune functions and found the 
absence of lymphoproliferative responses and IL-2 production in response to recall/viral antigens 
which could be induced by immune therapy with IL-2 and GM-CSF. Those immune modulating 
treatments, however, are actually still inaccessible for the developing world.  
 
Another major problem related to the use of HAART is caused by resistance. In our study on the 
latent HIV-reservoir we show the archiving of all replication competent HIV variants. Retrieving 
an individuals’ therapy history is possible by analysing HIV-proviral sequences. Archiving 
implicates that once resistance arose, it can permanently jeopardize future treatment options. This 
emphasizes the importance of preventing resistance through adherence and optimal treatment 
regimens. World wide programs trying to prevent mother to child transmission (MTCT) with 
mono-or bi-therapy, fast elicit resistance linked mutations 61-69. Depending on the time this sub-
optimal treatment is given and on the antiretroviral drugs used, these mutations will develop with 
a different rate. Moreover, this strategy is not only associated with much higher HIV transmission 
rate, but also transmission of  resistant virus to the child 70. Future treatment options of those 
HIV-infected women and children can hereby seriously be restricted. Studies have to investigate 
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if previous used preventive MTCT programs are decreasing the efficacy of later started HAART 
in these HIV infected patients. Far most the best option is to use triple-drug MTCT prophylaxis, 
which has been proven highly efficient despite the standardized approach in the resource poor 
setting 61.  
Big concern exists about infection with resistant viruses 71. Reported percentages of HIV-
infection with resistant viruses are between 10 and 30% 72-74. This percentage gives an idea of the 
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HAART has been of great benefit in reducing morbidity and mortality related to HIV/AIDS in 
the western world. However, as worldwide only 17% of the HIV-infected patients in need of 
therapy are receiving HAART, the pandemic is still expanding. Especially in the developing 
world, where 95% of the people with HIV/AIDS are living, the situation is dramatic. Our 
epidemiologic overview shows the urgency to enhance efforts against this number one killer 
worldwide. There is an urgent need for broader preventive strategies, higher access to 
treatment and in the future, hopefully, an efficient vaccine or new therapies leading to a 
harmless symbiosis of the virus with his host or to a total HIV eradication.   
 
5.2 HAART TREATMENT IN EARLY HIV-INFECTION 
 
Studies suggested that early treatment of an HIV-infection can be useful and sometimes lead 
to a control of viral replication after stopping therapy. We studied a cohort of 68 recently 
HIV-infected patients. In 40 of them HAART was started in the first 6 months of their HIV-
infection. Thirty-eight patients were retained for analysis. They were treated for different 
periods of time (mean: 17,3 months). The 28 remaining patients remained untreated and were 
followed as controls. VL, CD4 T cell percentages and HIV-specific immunity were followed 
after treatment interruption. Values were compared between treated (n=32) and untreated 
acute HIV-infected individuals (n=28).  
The treated patient group was found to have a longer VL suppression and higher CD4 T cell 
numbers after treatment interruption. This effect was seen throughout the follow-up period of 
3 years after treatment stop. HIV-specific immunity was not lost by early HAART. Moreover, 
our results show a correlation between high HIV-specific CD4 T cell IFN-γ production and 
VL suppression.  
Criteria for safely stopping HAART remain to be elucidated: candidate markers are CD4 T 
cell numbers, HIV-specific CD4 T cells and proviral load. This, however, needs to be 






5.3 HAART TREATMENT IN LATE HIV-INFECTION 
 
The clinical impact of HAART is most pronounced in late stage HIV-infection when HIV-
related symptoms are present. However, a controversial clinical deterioration after treatment 
instauration can be observed in some late stage HIV-infected patients. Symptoms, due to 
increased inflammatory responses are related to treatment induced immune restoration.  
We illustrated this IRIS in an HIV/TB co-infected patient. Serious symptoms developed after 
the instauration of TB and HIV-treatment. Prednisolone gave relieve of general symptoms, 
while lymph node abscesses continued to appear and persisted up to 8 months after treatment 
start. After 1 year TB treatment was stopped. The patient remained in good clinical condition 
for 3 years. She then developed again lymph node abscesses, which were Ziehl Nielsen 
positive, while specific culture was negative. She was again treated for 9 months with 
tuberculostatic drugs. Symptoms disappeared again and since 2 years she is in good clinical 
condition.  
The incidence of IRIS is increasing as access to care is rising. By treating HIV-infection 
earlier in the disease course, IRIS could be avoided. This would need an earlier diagnosis, a 
higher awareness of possible HIV-infection and a better health education. For people 
consulting with extremely low CD4 T cell counts, immune modulating therapies could be 
useful in the prevention or management of IRIS.   
 
5.4 HAART AND LATENT RESISTANT HIV 
 
Viral latency is the major impediment to total eradication of HIV with the current ART. 
Resistance, on the other hand, compromises the efficacy of HAART. We studied the 
behaviour of the HIV-reservoir in a cohort of 11 patients in whom resistant virus evolved after 
sub-optimal ART. The patients were switched to an efficient HAART regimen resulting in 
viral suppression to undetectable levels. After a mean treatment period of 59 months, blood 
samples of these 11 patients were analysed for HIV proviral sequences. The presence of 
resistant HIV variants could be revealed in 10 of the 11 patients. The patient in whom no 
resistant HIV variants were found had been on sub-optimal therapy for the shortest period of 
time (11 months). A positive correlation was found between the period on sub-optimal 
HAART and the percentage resistant HIV variants in the HIV proviral pool.  
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 We conclude that archiving of all replication competent HIV variants over the patient’s 
disease history, takes place. Recycling of drugs to which resistance arose seems therefore 
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Het introduceren van Highly Active Antiretrovirale Therapie (HAART) heeft een groot 
aandeel gehad in het verminderen van de morbiditeit en de mortaliteit veroorzaakt door 
HIV/AIDS in de westerse wereld. Nochtans neemt de pandemie nog steeds toe, vooral omdat 
wereldwijd slechts 17% van de HIV-geïnfecteerde patiënten die behandeling nodig hebben, 
HAART krijgen. Voornamelijk in de ontwikkelingslanden, waar 95% van de patiënten met 
HIV/AIDS leven, is de situatie dramatisch. Ons epidemiologisch overzicht benadrukt de 
noodzaak om de inspanningen tegen deze wereldwijde nummer één doodsoorzaak te 
verhogen. Er is een dringende nood aan uitbreiding van preventieve strategieën en 
toegankelijkheid tot medische zorgen. Voor de toekomst wordt gehoopt op een efficiënt 
vaccin of nieuwe therapieën die tot een onschadelijke symbiose leiden van het virus met zijn 
gastheer of tot de volledige eliminatie van het virus.  
 
5.2 HAART BEHANDELING IN DE VROEGE HIV-INFECTIE 
      
Studies suggereren dat vroege behandeling van de HIV infectie nuttig kan zijn en soms leidt 
tot langdurige onderdrukking van HIV na onderbreking van de behandeling. We bestudeerden 
een cohorte van 68 recent HIV-geïnfecteerde patiënten. In 40 van hen werd HAART gestart in 
de eerste 6 maanden van hun HIV-infectie. Tweeëndertig patiënten werden weerhouden voor 
analyse. Deze patiënten werden behandeld gedurende verschillende tijdsperiodes (gemiddeld: 
17,3 maanden). Achtentwintig patiënten bleven onbehandeld en werden gevolgd als controles. 
Virale load (VL), CD4 T cel percentages en HIV-specifieke immuniteit werden opgevolgd na 
onderbreking van de behandeling. Waarden werden vergeleken tussen behandelde patiënten 
(n=32) en  niet behandelde acuut HIV-geïnfecteerde individuen (n=28).  
De behandelde patiënten groep bleek een langduriger suppressie van de VL en hogere CD4 T 
cel aantallen te hebben na therapie onderbreking. Dit verschil werd gezien gedurende de 
volledige follow-up periode van 3 jaar na het stoppen van de behandeling. HIV-specifieke 
immuniteit ging niet verloren door vroege HAART. Onze resultaten toonden een 
overeenkomst tussen een hoge IFN-γ productie door HIV-specifieke CD4 T cellen en de 
suppressie van de VL.  
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Criteria voor het veilig stoppen van HAART moeten nog gedefinieerd worden: mogelijke 
parameters zijn CD4 T cel aantallen, HIV-specifieke CD4 T cellen en proviral lading. Dit 
moet echter onderzocht worden in een studie met langere behandelingsperiode en met langere 
follow-up tijd.     
 
5.3 HAART BEHANDELING IN DE LATE HIV-INFECTIE 
 
De klinische invloed van HAART is meest uitgesproken in de late fase van de HIV-infectie 
wanneer HIV-gerelateerde symptomen aanwezig zijn. Nochtans kan men in sommige HIV-
geïnfecteerde patiënten in deze late fase een tegenstrijdige klinische achteruitgang zien na het 
instellen van de behandeling. Symptomen, toegeschreven aan een toegenomen inflammatoir 
antwoord worden veroorzaakt door het immuun herstel geïnduceerd door de behandeling.  
We illustreren deze IRIS in een HIV/TB gecoïnfecteerde patiënte. Ze ontwikkelde ernstige 
symptomen na het instellen van de TB en HIV-behandeling. Prednisolone gaf verlichting van 
de algemene symptomen, terwijl lymfe knoop abcessen bleven verschijnen en aanwezig 
bleven tot 8 maand na het opstarten van de behandeling. Na 1 jaar werd de TB behandeling 
gestopt. De patiënt bleef in goede conditie gedurende 3 jaar. Dan ontwikkelde zij terug lymfe 
knoop abcessen, die Ziehl Nielsen positief waren, terwijl de specifieke cultuur negatief was. 
Ze werd opnieuw behandeld met tuberculostatica gedurende 9 maand. Symptomen verdwenen 
terug en ze is nu in goede algemene conditie sinds 2 jaar.  
De incidentie van IRIS neemt toe aangezien de toegang tot medische zorgen stijgt. Door HIV-
infectie in een vroeger stadium te behandelen, kan IRIS vermeden worden. Dit vergt een 
vroegere diagnose, een hoger vermoeden van een mogelijke HIV-infectie en een betere 
gezondheidsopvoeding. Voor mensen die consulteren met een extreem laag aantal CD4 T 
cellen, kan immuun modulerende behandeling nuttig zijn in de preventie of de behandeling 
van IRIS. 
 
5.4 HAART EN LATENTE, RESISTENTE HIV-INFECTIE 
 
Virale latentie is de voornaamste struikelsteen voor volledige uitroeiing van HIV met de 
huidige ART. Resistentie, aan de andere kant, vermindert de doeltreffendheid van HAART. 
We bestudeerden het gedrag van het HIV-reservoir in 11 patiënten die resistentie 
ontwikkelden na sub-optimale behandeling. De patiënten werden vervolgens behandeld met 
een efficiënt HAART regime wat resulteerde in onderdrukking van het virus tot niet te 
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detecteren plasma spiegels. Na een gemiddelde behandelingsperiode van 59 maanden, werden 
bloedstalen van deze 11 patiënten geanalyseerd voor HIV provirale sequenties. De 
aanwezigheid van resistente HIV varianten kon aangetoond worden in 10 van de 11 patiënten. 
De patiënt bij wie geen resistente HIV varianten werden gevonden was voor de kortste 
periode behandeld met sub-optimale therapie (11 maanden). Een positieve relatie werd 
gevonden tussen de periode van sub-optimale HAART en het percentage resistente HIV 
varianten in de provirale pool.  
We besluiten dat lange termijn archivering van alle replicatiecompetente HIV varianten 
optreedt. Hergebruik van medicatie tegen dewelke resistentie optrad lijkt daardoor 
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